<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J. Alzheimers Dis</journal-id><journal-id journal-id-type="publisher-id">JAD</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><issn-l>1387-2877</issn-l><publisher><publisher-name>IOS Press</publisher-name><publisher-loc>Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4698155</article-id><article-id pub-id-type="publisher-id">JAD150398</article-id><article-id pub-id-type="doi">10.3233/JAD-150398</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Transcriptomics Profiling of Alzheimer&#x02019;s Disease Reveal
Neurovascular Defects, Altered Amyloid-&#x003b2; Homeostasis,
and&#x000a0;Deregulated Expression of Long Noncoding&#x000a0;RNAs</article-title><alt-title alt-title-type="left-running-head">M. Magistri et al.</alt-title><alt-title alt-title-type="right-running-head">Transcriptomics Profiling of Alzheimer&#x02019;s Disease</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Magistri</surname><given-names>Marco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Velmeshev</surname><given-names>Dmitry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Makhmutova</surname><given-names>Madina</given-names></name></contrib><contrib contrib-type="author"><name><surname>Faghihi</surname><given-names>Mohammad Ali</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="aff1">Center for Therapeutic Innovation &#x00026; Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Dr. Mohammad A. Faghihi, Center for Therapeutic Innovation &#x00026; Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1501 NW 10th Ave, BRB 508, Miami, FL 33136, USA. <email>mohammad.ali.faghihi@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2015</year></pub-date><volume>48</volume><issue>3</issue><fpage>647</fpage><lpage>665</lpage><history><date date-type="accepted"><day>22</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>IOS Press and the authors. All rights reserved</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License</ext-link>, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>Abstract</title><p>The underlying genetic variations of late-onset Alzheimer&#x02019;s disease (LOAD) cases remain largely unknown. A combination of genetic variations with variable penetrance and lifetime epigenetic factors may converge on transcriptomic alterations that drive LOAD pathological process. Transcriptome profiling using deep sequencing technology offers insight into common altered pathways regardless of underpinning genetic or epigenetic factors and thus represents an ideal tool to investigate molecular mechanisms related to the pathophysiology of LOAD. We performed directional RNA sequencing on high quality RNA samples extracted from hippocampi of LOAD and age-matched controls. We further validated our data using qRT-PCR on a larger set of postmortem brain tissues, confirming downregulation of the gene encoding substance P (<italic>TAC1</italic>) and upregulation of the gene encoding the plasminogen activator inhibitor-1 (<italic>SERPINE1</italic>). Pathway analysis indicates dysregulation in neural communication, cerebral vasculature, and amyloid-&#x003b2; clearance. Beside protein coding genes, we identified several annotated and non-annotated long noncoding RNAs that are differentially expressed in LOAD brain tissues, three of them are activity-dependent regulated and one is induced by A&#x003b2;<sub>1&#x000a0;-&#x000a0;42</sub> exposure of human neural cells. Our data provide a comprehensive list of transcriptomics alterations in LOAD hippocampi and warrant holistic approach including both coding and non-coding RNAs in functional studies aimed to understand the pathophysiology of LOAD.</p></abstract><kwd-group><title>Keywords</title><kwd>Alzheimer&#x02019;s disease</kwd><kwd>amyloid homeostasis</kwd><kwd>cerebral vasculature</kwd><kwd>long noncoding RNAs</kwd><kwd>natural antisense transcripts</kwd><kwd>RNA sequencing</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>INTRODUCTION</title><p>Alzheimer&#x02019;s disease (AD) is a complex age-related neurodegenerative disorder characterized by progressive loss of synapses and neurons in the hippocampus and cortex, which is associated with gradual decline in short-term memory and cognitive functions. It affects more than 36 million people worldwide, and by the year 2050, the number of people affected by AD may triple [<xref rid="r1" ref-type="bibr">1, 2</xref>]. At the molecular level, the hallmarks of AD are the presence of amyloid-&#x003b2; (A&#x003b2;) plaques and neurofibrillary tangles (NFTs) in the brains of patients affected by the disease. Mutations in genes involved in A&#x003b2; biogenesis (<italic>APP</italic>, <italic>PS1</italic>, and <italic>PS2</italic>) have been found in the small percentage (&#x0223c;13% ) of cases of familial early-onset AD. Despite an enormous research effort, causative genetic alterations responsible for the most cases of late-onset AD (LOAD) remain largely unknown, suggesting a polygenic multifactorial type of inheritance. The <italic>&#x0025b;</italic>4 allele of apolipoprotein E (<italic>APOE</italic>) is the major genetic risk factor of LOAD [<xref rid="r3" ref-type="bibr">3</xref>]; however, recent genome wide association studies have found common low-penetrance variants associated with LOAD in more than 20 genomic loci [<xref rid="r4" ref-type="bibr">4&#x02013;8</xref>]. Current research is still a long way from the ultimate goal of revealing clear factors that can help in the diagnosis, prevention, and treatment of the disease. Based on the &#x02018;Common Disease, Common Variant&#x02019; hypothesis, genetic variations with high frequency and low penetrance might be the major contributors to LOAD. Alternatively, the &#x02018;Common Disease, Rare Variant&#x02019; hypothesis suggests that rare variations with high penetrance might explain genetic susceptibility to LOAD. Above both of these genetic variation hypotheses, epigenetic factors and lifelong environmental or nutritional impetuses might contribute to disease without any apparent genetic background. The low heritability and absence of clear genetic correlates implies that LOAD may represent a common pathogenic process resulting from an interplay of different genetic, environmental, and epigenetic factors [<xref rid="r9" ref-type="bibr">9</xref>]. In an attempt to investigate transcriptomic changes that take place in LOAD, several gene expression profile studies on postmortem brain tissues from AD patients have been performed mostly using microarray technology [<xref rid="r10" ref-type="bibr">10</xref>]. These studies identified AD specific alterations in cellular processes such as mitochondrial activity, intracellular signaling, and neuroinflammation but, unfortunately, little consensus among these studies or meaningful insight into AD pathophysiology has been obtained (reviewed in [<xref rid="r10" ref-type="bibr">10</xref>]). This is likely due to inherent limitations of microarray technology, which has since been largely replaced by next generation RNA sequencing (RNAseq) [<xref rid="r11" ref-type="bibr">11</xref>]. RNAseq provides a more comprehensive and accurate transcriptomic analysis with the main advantage being the accurate analysis of all RNA species, including non-protein coding RNAs (ncRNAs) [<xref rid="r12" ref-type="bibr">12</xref>] and alternatively spliced isoforms, thus representing an extraordinary tool to study transcriptomic changes associated with complex diseases pathogenesis [<xref rid="r13" ref-type="bibr">13</xref>].</p><p>Here we investigated transcriptomic changes in the hippocampus of AD patients with directional RNA sequencing and analyzed the data using an experimentally validated bioinformatics pipeline that allows the discovery of novel RNA transcripts and the precise measurements of protein- and non protein-coding genes expression. Our study provides for the first time a comprehensive and experimentally validated data set of transcriptomic changes occurring in the hippocampus of LOAD patients and identifies conceptually novel molecular targets that may play a role in the pathogenesis of LOAD.</p></sec><sec id="sec0010"><title>MATERIAL AND METHODS</title><sec id="sec0015"><title>Brain samples</title><p>Human brain samples were prepared from rapid autopsy brain tissue that had been obtained from The Branner Sun Health Research Institute. The average postmortem interval (PMI) for all the samples is 2.48&#x0200a;h (<xref ref-type="supplementary-material" rid="S1">Supplementary File 1</xref>). All enrolled subjects or legal representatives had signed a Sun Health Research Institutional Review Board&#x02013;approved informed consent form allowing both clinical assessments during life and several options for brain and bodily organ donation after death. Total RNA was isolated via CsCl purification from tissue dissected from specific regions of brain. Although not all regions were available from all cases, we examined a total of 118 RNA samples from superior frontal gyrus, entorhinal cortex, hippocampus, and cerebellum in this study. Drs. Douglas E. Wood and Barbara G. Sahagan at Central Nervous System Discovery, Pfizer Global Research and Development, USA previously gifted these RNA samples to our laboratory, which were utilized in our published work [<xref rid="r14" ref-type="bibr">14</xref>]. Tissue sample information was received from the Banner Sun Health Research Institute. Complete clinicopathological information on the samples are provided as <xref ref-type="supplementary-material" rid="S1">Supplementary File 1</xref>.</p><p>Average plaque density was scored in different brain regions (frontal, temporal, and parietal lobes, hippocampus, and entorhinal cortex) according to the CERAD templates [<xref rid="r15" ref-type="bibr">15</xref>]. Values: 0&#x0200a;=&#x0200a;none; 1&#x0200a;=&#x0200a;sparse; 2&#x0200a;=&#x0200a;moderate; 3&#x0200a;=&#x0200a;frequent; 9&#x0200a;=&#x0200a;unknown or unavailable. Average NFT density was scored in different brain regions (frontal, temporal, and parietal lobes, hippocampus, and entorhinal cortex) according to the CERAD templates [<xref rid="r15" ref-type="bibr">15</xref>]. Values: 0&#x0200a;=&#x0200a;none; 1&#x0200a;=&#x0200a;sparse; 2&#x0200a;=&#x0200a;moderate; 3&#x0200a;=&#x0200a;frequent; 9&#x0200a;=&#x0200a;unknown or unavailable. The Braak stage describes the topographical progression of NFTs, as well as associated dystrophic neurites and neuropil threads, throughout the transentorhinal and entorhinal areas, CA1 subfield of the hippocampus, amygdala, and cerebral neocortex. Evaluations was made according to the original publication [<xref rid="r16" ref-type="bibr">16</xref>]. NIA-Regan criteria are consensus recommendation for the diagnosis of AD developed by a consensus committee jointly sponsored by the National Institute on Aging (NIA) and the Reagan Institute [<xref rid="r17" ref-type="bibr">17</xref>]. The guidelines suggested that certain combinations of CERAD neuritic plaque density and Braak neurofibrillary stage confer probabilistic estimates of their likelihood for being responsible for dementia. Thus, there are low, intermediate, and high likelihoods for dementia due to AD histopathology. The category &#x0201c;not AD&#x0201d; is checked off if there are either no plaques at all or no tangles at all. The category &#x0201c;criteria not met&#x0201d; is checked off if the subject was not demented.</p></sec><sec id="sec0020"><title>Library preparation</title><p>RNA quality was measured using Agilent Bioanalyzer RNA nano chip and the RNA integrity number (RIN) of the samples was between 6.5 and 8.6. RNA samples were prepared for directional RNA sequencing using a modified version of the Illumina Directional mRNA-Seq sample preparation protocol. Briefly, 1<italic>&#x003bc;</italic>g of total RNA was processed using Ribo-ZeroTM rRNA Removal Kits (Epibio) to remove ribosomal RNAs. Ribosome-depleted RNA was treated with phosphatase before being treated with T4 polynucleotide kinase (PNK). PNK-treated RNA was then purified with the QIAGEN RNeasy column purification kit and different 3&#x02019; and 5&#x02019; RNA adapters were ligated to both ends of the RNA in separate reactions. Next, the RNA was reverse transcribed and PCR amplified on regular thermo cyclers for 15 cycles. PCR products were purified using AMPure beads. RNA sequencing libraries were validated using the Agilent Bioanalyzer High Sensitivity DNA kit and sequenced using the Illumina HiSeq2000 platform at the Genomics sequencing core at the Hussman Institute for Human Genomics, University of Miami. Each sample was run in a single lane of a flow cell to increase depth of sequencing.</p></sec><sec id="sec0025"><title>Differential gene expression analysis</title><p>RankProd R package [<xref rid="r18" ref-type="bibr">18</xref>] was used to perform gene expression analysis of RNAseq data. First, genes were filtered based on read coverage and only genes having average coverage of at least 20 reads in one of the two groups were retained. These FPKM values were used as input for RankProd analysis, which ranks genes in each replicate from the experimental group based on their up- or downregulation compared to the control group. Then, it derives rank product (RP), which is the product of all the individual ranks for a given gene in each replicate. Genes with small RP are consistently up- or downregulated in several experimental replicate conditions. <italic>P</italic> value for each gene is calculated based on permutation tests and reflects the number of times RP values smaller than or equal to a given experimental RP value occur in the 100 random experiments. To correct for multiple comparisons, the percentage of false-positives (pfp) equivalent to FDR is calculated by dividing the <italic>p</italic> value by the relative rank of a gene in the gene list. pfp value of 0.1 was used as the cutoff for statistical significance.</p></sec><sec id="sec0030"><title>Pathway analysis</title><p>Differentially expressed protein-coding genes were utilized as the input list to perform enrichment analysis with GeneGo MetaCore from Thomson Reuters. GeneGo Enrichment analysis tool uses manually annotated reference pathways to calculate the enrichment of a given list of genes in each pathway and provides <italic>p</italic>&#x000a0;value and FDR value that reflect the chance the given number of genes from a pathway would appear in the list by chance. Only pathways with FDR less than 0.1 were considered as significantly enriched.</p></sec><sec id="sec0035"><title>Quantitative real time PCR (qRT-PCR)</title><p>All RNA samples were treated with DNase to remove any contaminant genomic DNA. RNA was then reverse transcribed using Superscript first strand kit (Life Technologies) and the cDNA was diluted and used as template for SYBR Green or TaqMan qPCR on the ABI 7900 (Life Technologies). RNA from human brain, heart, kidney, liver, lung, and muscle was purchased from Life Technologies. Human neurons and astrocytes RNA have been purchased from ScienceCell Research Laboratories, cat# 1525 and cat# 1585 respectively. SERPINE1, TAC1, PGK1 and &#x003b2;-ACTIN TaqMan assays were purchased from Life Technologies. Primers used for SYBR green qRT-PCR to validate and measure the expression of novel ncRNAs are listed in <xref ref-type="supplementary-material" rid="S7">Supplementary File 7</xref>. Non-coding RNAs expression was measured using Power SYBR Green (Life Technologies). For all qRT-PCR reactions, we included three technical replicates. To compare the expression of genes across different cellular compartment, GraphPad prism software was used to perform ANOVA followed by Tukey <italic>post-hoc</italic> test. A <italic>p</italic> value of below 0.05 was considered as statistically significant. The Student&#x02019;s <italic>t</italic>-test was used to compare the expression between the normal brain and LOAD.</p></sec><sec id="sec0040"><title>Human neural stem cells (hNSCs) culture, differentiation, and treatment</title><p>Human NSCs are isolated from three human fetal brains collected from 3rd trimester aborted fetuses, that we receive from the Birth Defects Research Lab at the University of Washington in Seattle, and maintained in culture as neurospheres as previously reported [<xref rid="r19" ref-type="bibr">19</xref>]. Briefly, dissected brain tissues are mechanically dissociated into single cell suspensions and seeded at a density of 5&#x000d7;10<sup>6</sup> cells in 75-mm tissue culture flasks in Human Neural Progenitor Media from Lonza in the presence of EGF and FGF2. After 7&#x02013;10 days of culture, NSCs cells form neurospheres colonies, whereas other cell types remain in suspension as single cells or attach to the bottom of the flask. The isolated hNSCs can be cultured as neurospheres in suspension for several months. Alternatively hNSCs can be differentiated <italic>in vitro</italic> into a mixed population of neurons and astrocytes. Briefly, to induce differentiation, neurospheres are disaggregated into single cells and plated in 6-well plates coated with poly-L-Ornythine (PLO) and laminin in the presence of B27/Neurobasal media in absence of growth factors for 21 days. The differentiated culture contains a mix of neural cell lineages including astrocytes and neurons as well as their progenitor cells.</p></sec><sec id="sec0045"><title>KCL depolarization</title><p>To induce cellular depolarization, NSCs are differentiated for 21 days in the presence of B27 (without retinoic acid) into a mixed population of neurons and astrocytes. This mixed population of neural cells is depolarized utilizing 50&#x0200a;mM KCl for 1&#x0200a;h prior to RNA extraction.</p></sec><sec id="sec0050"><title>Preparation of soluble A&#x003b2;<sub>42</sub> peptides and cell treatment</title><p>1&#x0200a;mg of lyophilized A&#x003b2;<sub>42</sub> peptide <italic>&#x003c9;</italic><italic>&#x003b1;</italic><italic>&#x003c3;</italic> purchased from Sigma Aldrich (Catalog Number A9810) and dissolved in 1&#x0200a;mL of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to promote formation of <italic>&#x003b1;</italic>-helix and minimize &#x003b2;-sheet structure. The solution was air-dried in a fume hood and the resulting clear film was re-suspended in DMSO to a stock concentration of 1&#x0200a;mM. NSCs are differentiated for 21 days in the presence of B27 (without retinoic acid) into a mixed population of neurons and astrocytes. This mixed population of neural cells is exposed to 10<italic>&#x003bc;</italic>M of soluble A&#x003b2;<sub>42</sub> for 48&#x0200a;h prior to RNA extraction.</p></sec><sec id="sec0055"><title>Cellular fractionation</title><p>Human NSCs were fractionated into cytosol, nucleoplasm and chromatin using a modified NE-PER Kit (PIERCE) and RNA was isolated using a combination of two protocols: Trizol (Life Technologies) and RNeasy Mini Kit (QIAGEN). The kit was used as described in the protocol except the insoluble pellet after nucleoplasm extraction was washed with PBS once and re-suspended in Trizol reagent until completely dissolved before proceeding to RNA extraction from the chromatin fraction.</p></sec><sec id="sec0060"><title>Immunostaining</title><p>Human neural stem cells were plated on 8-well glass chamber slides (Millipore, PEZGS0816) coated with poly-l-ornithine for 3&#x0200a;h and laminin overnight. Cells were plated at the density of 40,000 cells per well and differentiated in Neurobasal media containing B27 supplement without vitamin A in absence of growth factors for 21 days before staining. After 21 days, cells were fixed with 4% formaldehyde for 10&#x0200a;min, permeabilized with 0.2% triton X, and incubated for 1&#x0200a;h in 20% goat serum to prevent non-specific binding of primary antibodies. Cells were then incubated with primary antibody overnight at 4&#x000b0;C, subsequently cells were washed 3 times with PBS and incubated with fluorescently labeled secondary antibodies for 2&#x0200a;h at room temperature. Antibodies used: rabbit anti-&#x003b2;III-tubulin (Covance, MRB-435P), chicken anti-MAP2 (Abcam, ab5392), mouse anti-GFAP (Millipore, MAB360).</p></sec></sec><sec id="sec0065"><title>RESULTS</title><sec id="sec0070"><title>Development of a bioinformatics pipeline for novel RNAs discovery and accurate gene expression analysis of RNA sequencing data</title><p>RNA deep sequencing (RNAseq) data analysis currently represents the bottleneck for the application of this powerful technology since an experimentally validated and globally accepted pipeline for data analysis is still missing. In this study, we developed and experimentally validated a computational approach based on TopHat [<xref rid="r20" ref-type="bibr">20</xref>] and Cufflinks [<xref rid="r21" ref-type="bibr">21</xref>] packages to accurately measure gene expression and to discover and annotate novel RNA transcripts. As schematically represented in <xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1A</xref>, TopHat is used to align reads to the human genome, while transcriptome reconstruction of each individual sample is performed using Cufflinks. Reconstructed transcriptomes for each individual samples are compared to each other using Cuffcompare that also merges overlapping constructs and annotates them according to the reference transcriptome provided (Ensembl GRCh37) [<xref rid="r22" ref-type="bibr">22</xref>]. In order to discriminate real transcripts from sequencing artifacts we adopted a filtering strategy based of two main criteria: 1) the presence of at least one splice junction in the transcripts and 2) the recurrent expression of single exon transcripts across multiple samples. We noted that applying this filtering strategy dramatically reduces the number of fragments originating from introns, repeat transcripts and polymerase run-off RNAs.</p><p>After filtering, annotated transcripts are subdivided based on Ensembl classification in protein coding genes, long intergenic non-coding RNAs (lincRNAs) and natural antisense RNAs transcripts (NATs) (<xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1A</xref>). Non-annotated transcripts are divided into intergenic RNAs, located in between and non-overlapping other transcripts; and NATs, overlapping other transcripts in the opposite orientation. These novel transcripts may encode for novel proteins or may be noncoding RNAs. To assess the protein coding potential of these novel transcripts we used the coding potential assessment tool (CPAT), an alignment free method that rapidly recognizes coding and noncoding RNAs [<xref rid="r23" ref-type="bibr">23</xref>]. Cuffdiff module of Cufflinks is utilized to retrieve Fragment Per Kilobase per Million fragments mapped (FPKM) values for both annotated and novel genes that are then used to calculate differential gene expression applying Rank Products. Importantly, we noted a certain level of reads coverage to be necessary in order to obtain reliable differential expression analysis. By comparing qRT-PCR with RNAseq data we established coverage of 20 reads per transcript to be the minimum number of reads required to achieve reliable differential expression analysis.</p></sec><sec id="sec0075"><title>The Alzheimer&#x02019;s disease transcriptome</title><p>We performed directional RNA sequencing using Illumina Hiseq 2000 on RNA extracted from the hippocampi of four patients affected by LOAD and of four age-matched control individuals (<xref ref-type="table" rid="jad-48-3-jad150398-t001">Table&#x000a0;1</xref> and <xref ref-type="supplementary-material" rid="S1">Supplementary File 1</xref>). Directional RNAseq was performed running one sample per lane and we generated &#x0223c;177.000.000 reads per sample, yielding excellent coverage and sequencing depth (<xref ref-type="table" rid="jad-48-3-jad150398-t002">Tables&#x000a0;2</xref> and <xref ref-type="table" rid="jad-48-3-jad150398-t003">3</xref>). Directional sequencing technique, unlike conventional sequencing methods, keeps strand-of-origin information in order to accurately align reads from positive and negative DNA strands. The strand-specific alignment helps identifying NATs and to accurately measure expression values of both sense and antisense RNA transcripts. We applied our bioinformatics pipeline and identified 13,054 annotated genes to be expressed in at least one of the sequenced samples (<xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1B</xref>). We further subdivided these annotated genes based on Ensembl classification into protein coding genes (12,132), lincRNAs (499), and NATs (423) (<xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1B</xref>). We also found 2,082 novel lincRNAs and 443 novel NATs to be expressed in at least one of the analyzed samples. Of these novel transcripts, 51 intergenic RNAs and 32 antisense RNAs are predicted to have protein-coding potential by CPAT analysis, thus representing potential novel protein-coding genes (<xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1B</xref>). A complete list of all RNA transcripts retrieved from sequencing is provided as additional material (<xref ref-type="supplementary-material" rid="S2">Supplementary File 2</xref>) and the raw data discussed in this publication have been deposited in NCBI&#x02019;s Gene Expression Omnibus [<xref rid="r24" ref-type="bibr">24, 25</xref>] and are accessible through GEO Series accession number GSE67333.</p><p>In order to validate the accuracy of reconstruction and expression of novel RNA transcripts, we designed primers spanning exons junctions and performed qRT-PCR on RNA extracted from human hippocampus, cerebellum, and prefrontal cortex. With this method, we were able to validate the expression of 14 not-previously annotated ncRNAs, confirming the accuracy of our bioinformatics analysis in reconstructing and detecting expression of novel ncRNA transcripts (<xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1C</xref>).</p><p>To identify AD specific transcriptomic changes, we retrieved FPKM values for genes utilizing Cuffdiff and performed Rank Products analysis [<xref rid="r18" ref-type="bibr">18, 26</xref>] to obtain <italic>q</italic> values corrected for multiple comparison. As a criterion for determine differentially expressed genes, we used percentage of false positive (pfp), which is the equivalent of false discovery rate, at &#x0003c;0.1. In order to detect potential outlier samples, we utilized hierarchical clustering followed by plotting a heatmap of log transformed FPKM values for each sample. The hierarchical clustering was performed by calculating Euclidian distance of logarithm of FPKM values for differentially expressed</p><p>genes between each of the 4 control and 4 AD samples. As shown in <xref ref-type="fig" rid="jad-48-3-jad150398-g001">Fig.&#x000a0;1D</xref>, control samples clustered together, as well as AD samples, indicating the absence of obvious outlier samples in our analysis. Differential expression analysis identified 143 protein coding genes, 90 lincRNAs, 31 antisense RNAs, and 1 novel putative protein coding gene to be differentially expressed between AD and control (<xref ref-type="fig" rid="jad-48-3-jad150398-g002">Fig.&#x000a0;2A</xref> and <xref ref-type="supplementary-material" rid="S3">Supplementary File 3</xref>). Three of the AD samples we selected for sequencing were Braak stage VI and the remaining sample was stage V. Braak stage of V and VI indicate the presence of NFT in neocortical regions and this typically indicates with high probability an advanced stage of the disease. These cases of AD could be characterized by extensive neuronal cell death and presence of gliosis in the brain, and this could results in differential expression of cell-type specific genes in our data set. To verify this possibility, we looked at the expression of known neuronal, astroglial, and microglial markers in Control and AD hippocampi from our RNAseq data. We observed no changes in the expression of neuronal markers: DCX (Fc: 1.02, pfp: 1.07), <italic>MAP2</italic> (Fc: 0.74, pfp: 0.99), <italic>NFH</italic> (Fc: 0.73, pfp: 0.99), <italic>NEFM</italic> (Fc: 0.71, pfp: 0.99), <italic>RBFOX3</italic> (Fc: 0.92, pfp: 1). No changes in the expression of astroglial markers: <italic>GFAP</italic> (Fc: 1.4, pfp: 0.8), <italic>AQP4</italic> (Fc: 1.2, pfp: 0.99), <italic>ALDH1L1</italic> (Fc: 1.22, pfp: 0.98), SLC1A3 (Fc: 1.08, pfp: 0.99). No changes in the expression of microglial markers: <italic>PTPRC</italic> (Fc: 0.74, pfp: 0.99), <italic>AIF1</italic> (Fc: 0.74, pfp: 1.01). These data indicate that, although the AD samples we analyzed have high Braak score, they were not depleted of neurons and enriched of astroglia and microglia cells and that the differentially expressed genes from our analysis are not the results of an imbalance between the cellular populations between AD and CTRL hippocampi.</p><p>Interestingly, the proportion of differentially expressed genes is much higher for lincRNAs and NATs compared to protein coding genes, suggesting substantial alteration of noncoding part of the genome in complex disorders such as LOAD and underestimated importance of long ncRNAs in pathophysiological processes underlying AD. Next, we achieved technical validation of RNAseq differential expression data by performing qRT-PCR analysis on the same RNA samples used for sequencing (<xref ref-type="fig" rid="jad-48-3-jad150398-g002">Fig.&#x000a0;2B</xref>). From RNAseq data we selected protein coding genes, lincRNAs and NATs with different expression levels and with a wide range of differential expression changes. We observed a high degree of correlation between log2 fold change differences from the two techniques for protein coding genes (<italic>n</italic>&#x0200a;=&#x0200a;6, <italic>p</italic>&#x0200a;=&#x0200a;0.0255, <italic>R</italic>&#x0200a;=&#x0200a;0.8666), lincRNAs (<italic>n</italic>&#x0200a;=&#x0200a;6, <italic>p</italic>&#x0200a;=&#x0200a;0.0121, <italic>R</italic>&#x0200a;=&#x0200a;0.9086), and AS (<italic>n</italic>&#x0200a;=&#x0200a;6, <italic>p</italic>&#x0200a;=&#x0200a;0.004, <italic>r</italic>&#x0200a;=&#x0200a;0.9481) (<xref ref-type="fig" rid="jad-48-3-jad150398-g002">Fig.&#x000a0;2B</xref>, <xref ref-type="supplementary-material" rid="S4">Supplementary File 4</xref>). Our RNAseq data provide an accurate assessment of gene expression levels and provide an experimentally validated and comprehensive catalog of expression changes of both protein-coding and non-coding genes in the hippocampus of patients suffering from LOAD.</p></sec><sec id="sec0080"><title>Dysregulation of neural communication and cerebral vasculature</title><p>Among the differentially expressed genes, we identified 61 protein coding genes to be expressed at lower levels and 82 at higher levels in AD hippocampi compared to control samples (pfp&#x0200a;&#x0003c; &#x0200a;0.1) (<xref ref-type="supplementary-material" rid="S3">Supplementary File 3</xref>). We utilized GeneGo MetaCore from Thomson Reuters to perform pathway analysis of differentially expressed genes, focusing our attention on process networks. This represents a comprehensive classification of biological processes based on a specific functional theme and defines involvement of genes in a process based on both the gene function and its known interactions with others genes related to the process. The two most enriched process networks are related to nerve impulse transmission and neuropeptide signaling (<xref ref-type="table" rid="jad-48-3-jad150398-t004">Table&#x000a0;4</xref>). The analysis of neuropeptide signaling pathways enriched for differentially regulated genes in our dataset revealed that the gene encoding substance P <italic>(TAC1)</italic> is downregulated in the hippocampi of AD patients compared to controls. The neurotrophic and neuroprotective activity of substance P, a neuropeptide involved in pain perception, has been demonstrated both <italic>in vitro</italic> and <italic>in vivo</italic> and reduced substance P levels and degeneration of substance P-immunopositive neurons in the brain of AD patients have been reported [<xref rid="r27" ref-type="bibr">27, 28</xref>]. In order to confirm our RNAseq results and to investigate the expression of <italic>TAC1</italic> in other brain regions, we decided to perform qRT-PCR analysis of the hippocampus, cerebellum, superior frontal gyrus, and entorhinal cortex of LOAD and control patients. We used a cohort of postmortem brain tissues representing four brain regions of 24 LOAD and 23 age- and gender-matched controls (<xref ref-type="supplementary-material" rid="S1">Supplementary File 1</xref>). Although not all of the brain regions were available from every individual, we had access to RNA form the cerebellum of 24 patients and 20 controls, hippocampus of 12 patients and 10 controls, entorhinal cortex of 8 patients and 9 controls, and superior frontal gyrus 17 patients and 18 controls. We could validate downregulation of substance P expression in the hippocampus and we observed a clear reduction, although not statistically significant, in the entorhinal cortex of AD patients compared to control (<xref ref-type="fig" rid="jad-48-3-jad150398-g003">Fig.&#x000a0;3A</xref>). There were no significant changes in <italic>TAC1</italic> expression in the superior frontal gyrus, or in the cerebellum (<xref ref-type="fig" rid="jad-48-3-jad150398-g003">Fig.&#x000a0;3A</xref>). Hippocampus and enthorinal cortex are among the first areas of the brain to be affected in AD, thus substance P loss in these two regions may represent an early event during the pathogenesis of the disease.</p><p>The other two statistically enriched process networks were muscle contraction and development blood vessel morphogenesis, indicating alterations in hippocampus vascularization in LOAD patients (<xref ref-type="table" rid="jad-48-3-jad150398-t004">Table&#x000a0;4</xref>).</p><p>Beside the genes belonging to this networks, we noticed, among the most differentially expressed protein coding genes in our RNAseq dataset, <italic>SERPINE1</italic> which is a regulator of vascular function and was previously associated with AD [<xref rid="r29" ref-type="bibr">29, 30</xref>]. According to our RNAseq data, <italic>SERPINE1</italic> was upregulated more than 3-fold in LOAD hippocampi. <italic>SERPINE1</italic> codes for the plasminogen activator inhibitor type-1 (PAI-1), which negatively regulates plasminogen activator proteins thus reducing the production of plasmin, a serine protease that plays a critical role in fibrinolysis, but also in mediating A&#x003b2; clearance [<xref rid="r31" ref-type="bibr">31</xref>]. Because of this dual role of <italic>SERPINE1</italic>, we decide to further study the expression of this gene in our bigger cohort of AD samples. qRT-PCR analysis of <italic>SERPINE1</italic> expression in different areas of the brain confirmed the abundant overexpression of <italic>SERPINE1</italic> in LOAD brain regions known to be affected by the disease: hippocampus (&#x0223c;11 fold), superior frontal gyrus (&#x0223c;5 fold), and entorhinal cortex (&#x0223c;10 fold) (<xref ref-type="fig" rid="jad-48-3-jad150398-g003">Fig.&#x000a0;3B</xref>). On the other hand, no differences in the expression of <italic>SERPINE1</italic> were observed in cerebellum, the brain region that is typically not affected by the disease (<xref ref-type="fig" rid="jad-48-3-jad150398-g003">Fig.&#x000a0;3B</xref>). Thus <italic>SERPINE1</italic> overexpression in specific areas of the brain may result in alteration of the cerebral vasculature and reduction of A&#x003b2; degradation.</p></sec><sec id="sec0085"><title>LOAD-dysregulated natural antisense transcripts</title><p>NATs are a class of lncRNAs that are transcribed from the opposite DNA strand of other RNA transcripts for which they share sequence complementarity. Antisense RNAs exert regulatory functions on protein-coding gene expression by different mechanisms both at the transcriptional and post-transcriptional level and the involvement of NATs in the pathophysiology of neuropsychiatric disorders has been previously demonstrated [<xref rid="r32" ref-type="bibr">32&#x02013;35</xref>]. Among the 31 differentially expressed NATs we noticed 21 (9 novel and 12 annotated) to be upregulated and 10 to be downregulated (4 novel and 6 annotated) in LOAD compared to control individuals (<xref ref-type="supplementary-material" rid="S3">Supplementary File 3</xref>). Among the most differentially expressed NATs are two multi-exonic RNAs that were not previously annotated and that we named <italic>HAO2-AS</italic> (XLOC_051561) and EBF3-AS (XLOC_083817). <italic>HAO2-AS</italic> is a 5 exons RNA of 488 nt transcribed from the opposite strand of the protein-coding gene <italic>HAO2</italic> on chromosome 1 (<xref ref-type="fig" rid="jad-48-3-jad150398-g004">Fig.&#x000a0;4A</xref>), while EBF3-AS is a 2-exons RNA of 842 nt transcribed from the opposite strand of the protein-coding gene <italic>EBF3</italic> on chromosome 10 (<xref ref-type="fig" rid="jad-48-3-jad150398-g004">Fig.&#x000a0;4A</xref>). 5&#x02019; RACE experiments validated the structure of these novel antisense ncRNAs and confirmed the accuracy of our RNAseq analysis in reconstructing and annotating novel transcripts (<xref ref-type="table" rid="jad-48-3-jad150398-t005">Table&#x000a0;5</xref>). These two antisense ncRNAs show tissue specific expression profiles with <italic>HAO2-AS</italic> most abundantly expresses in the heart and <italic>EBF3-AS</italic> most abundantly expressed in the brain (<xref ref-type="fig" rid="jad-48-3-jad150398-g004">Fig.&#x000a0;4B</xref>). Differential expression of these NATs in LOAD cases and their tissue-specific pattern of expression suggest that these NATs are not spurious random transcripts and further suggest that these transcripts might have important regulatory function in heart and brain.</p><p>In order to better characterized <italic>HAO2-AS</italic> and <italic>EBF3-AS</italic>, we performed subcellular fractionation of hNSCs isolated from three fetal brain tissues and extracted RNA from three separated fractions: cytosol, nucleoplasm, and chromatin. While protein coding genes are enriched in the cytoplasm (data not shown), both of the NATs are more abundantly expressed in the nucleoplasm and in the chromatin fractions (<xref ref-type="fig" rid="jad-48-3-jad150398-g004">Fig.&#x000a0;4C</xref>), suggesting their involvement in nuclear-related cellular processes such as epigenetic modification of histones that has been demonstrated for many long noncoding RNAs (lncRNAs) [<xref rid="r32" ref-type="bibr">32</xref>]. qRT-PCR analysis of EBF3-AS expression in different areas of the brain of AD cases and controls revealed the abundant overexpression of this NATs in AD brain regions known to be severely affected by the pathology (hippocampus, superior frontal gyrus, and entorhinal cortex) while no differences were observed in cerebellum (<xref ref-type="fig" rid="jad-48-3-jad150398-g004">Fig.&#x000a0;4D, E</xref>). Similar expression analysis for <italic>HAO2-AS</italic> revealed its upregulation in hippocampus and superior frontal gyrus while no differences were observed in the entorhinal cortex or cerebellum. Our data demonstrate that NATs are specifically dysregulated in brain regions affected by LOAD pathology and suggest involvement of this class of lncRNAs in nuclear-related cellular processes.</p></sec><sec id="sec0090"><title>LOAD-dysregulated long intergenic non-coding RNAs</title><p>LincRNAs are lncRNAs transcribed in intergenic regions [<xref rid="r36" ref-type="bibr">36, 37</xref>] that can exert regulatory functions at different levels and by different mechanisms [<xref rid="r38" ref-type="bibr">38</xref>]. Several independent studies confirmed lincRNAs to function as enhancer (eRNAs) to regulate gene expression of neighboring genes [<xref rid="r39" ref-type="bibr">39&#x02013;41</xref>] or to act as scaffold for the recruitment of chromatin modifying enzymes to regulate the epigenetic state of specific genomic loci [<xref rid="r42" ref-type="bibr">42&#x02013;44</xref>]. In our RNAseq analysis, we identified 89 lincRNAs to be differentially expressed in LOAD hippocampi compared to control, 72 of these are novel non-annotated RNA transcripts (<xref ref-type="supplementary-material" rid="S3">Supplementary File 3</xref>). Among the differentially expressed lincRNAs, two multiexonic lincRNAs were selected for qRT-PCR validation in our larger cohort of brain specimens of LOAD cases and control. <italic>AD-linc1</italic> (XLOC_753726) is a 264 nt long transcript composed of 14 exons transcribed from chromosome 9, while <italic>AD-linc2</italic> (XLOC_612449) is a 3 exon, 246 nt long transcript transcribed from chromosome 6 (<xref ref-type="fig" rid="jad-48-3-jad150398-g005">Fig.&#x000a0;5A</xref>). Both of these transcripts were upregulated in AD compared to control and because they were among the most highly expressed lincRNAs in our dataset, we decided to focus our attention on them. Expression of these two RNAs is tissue specific with <italic>AD-linc1</italic> being mostly expressed in the brain while <italic>AD-linc2</italic> is abundantly expressed in the heart and kidney and almost not detectable in the normal brain (<xref ref-type="fig" rid="jad-48-3-jad150398-g005">Fig.&#x000a0;5B</xref>). Similarly to what we have observed for antisense transcripts, we noticed a clear localization of these two lincRNAs in the chromatin compartment, suggesting their role in regulating chromatin structure (<xref ref-type="fig" rid="jad-48-3-jad150398-g005">Fig.&#x000a0;5C</xref>). qRT-PCR analysis of <italic>AD-linc1</italic> and <italic>AD-linc2</italic> expression in different brain regions of AD cases compare to controls revealed increased expression of these two ncRNAs in the hippocampus and superior frontal gyrus of AD patients while no differences were observed in cerebellum (<xref ref-type="fig" rid="jad-48-3-jad150398-g005">Fig.&#x000a0;5D, E</xref>). Although non-statistically significant, due to the limited number of cases available, we also observed the same trend in the entorhinal cortex where these two ncRNAs are more abundantly expressed in AD than in controls (<xref ref-type="fig" rid="jad-48-3-jad150398-g005">Fig.&#x000a0;5D, E</xref>).</p></sec><sec id="sec0095"><title>LOAD-lncRNAs are enriched in neuronal cells and are activity-dependent regulated</title><p>To evaluate in which specific cell type (neuronal or astroglial) LOAD-lncRNAs are enriched, we compared their expression in commercially available RNA extracted from human neurons and astrocytes. As shown in <xref ref-type="fig" rid="jad-48-3-jad150398-g006">Fig.&#x000a0;6A</xref>
<italic>AD-linc1</italic>, <italic>AD-linc2</italic>, <italic>HAO2-AS</italic>, and <italic>EBF3-AS</italic> are all enriched, although at different degrees, in neurons compared to astrocytes. Recent studies revealed that the expression of a subset of long ncRNAs is dynamically regulated during neuronal activation, thus suggesting their involvement in activity-dependent neuronal processes [<xref rid="r45" ref-type="bibr">45, 46</xref>]. To investigate LOAD-dysregulated lncRNAs transcriptional changes in response to activity and identify potential novel activity-dependent players in the pathology, we depolarized human neurons derived from the <italic>in vitro</italic> differentiation of human neural stem cells (hNSCs) (<xref ref-type="fig" rid="jad-48-3-jad150398-g006">Fig.&#x000a0;6B, C</xref> and <xref ref-type="supplementary-material" rid="S5">Supplementary File 5</xref>) and we measured the expression of <italic>AD-linc1, AD-linc2, HAO2-AS</italic>, and <italic>EBF3-AS</italic> using qRT-PCR. NSCs were isolated from human fetal brain and were cultured as floating neurospheres as previously described [<xref rid="r47" ref-type="bibr">47, 48</xref>]. KCl depolarization induced a canonical activity-dependent transcription of the immediate early gene c-FOS, thus confirming the ability of our neuronal culture to activate transcription of activity-dependent genes upon depolarization. Among the analyzed ncRNAs, <italic>AD-linc2, HAO2-AS</italic>, and <italic>EBF3-AS</italic> show activity-dependent transcription activation (<xref ref-type="fig" rid="jad-48-3-jad150398-g006">Fig.&#x000a0;6C</xref>). Recent studies have shown that lncRNAs expression changes in cells exposed to different stress conditions [<xref rid="r49" ref-type="bibr">49, 50</xref>]. To exclude the possibility that KCl treatment caused a generalized increase in lncRNAs transcription, we measured the expression of <italic>BDNF-AS, MALT1</italic>, and <italic>BACE1-AS</italic>, the last two being previously shown to be modulated by stress conditions [<xref rid="r14" ref-type="bibr">14, 51</xref>]. As shown in <xref ref-type="fig" rid="jad-48-3-jad150398-g006">Fig.&#x000a0;6C</xref>, expression of <italic>BDNF-AS, MALAT1</italic>, and <italic>BACE1-AS</italic> does not change in response to KCl treatment thus excluding a generalized increase of lncRNAs. Activity-dependent transcriptional regulation implies that these LOAD-lncRNAs might have functional regulatory significance. One possibility was that these activity-dependent lncRNAs could regulate the expression of nearby genes <italic>in cis</italic>. To test this hypothesis, we looked at changes in the expression of genes located in the same locus after KCl treatment. Interestingly we did not observe any changes upon KCl depolarization in the expression of nearby genes (<xref ref-type="supplementary-material" rid="S6">Supplementary File 6</xref>), indicating that transcriptional regulation of these activity-regulated lncRNAs is independent of nearby genes and suggesting a <italic>trans</italic>-acting mechanisms of function for these lncRNAs. Together our data suggest involvement of these lncRNAs in LOAD pathophysiology.</p></sec><sec id="sec0100"><title>Expression of AD-linc1 is induced by A&#x003b2;<sub>42</sub>
</title><p>Different long ncRNAs have been previously implicated in distinctive aspect of A&#x003b2;PP processing and a <italic>&#x003bc;&#x003c8;&#x003bb;o&#x003b9;&#x003b4;</italic> generation [<xref rid="r14" ref-type="bibr">14, 52&#x02013;54</xref>]; however, the effects of A&#x003b2; <italic>&#x0025b;&#x003be;&#x003c0;o&#x003c3;&#x003c5;&#x003c1;&#x0025b;</italic> on the expression of lncRNAs in human neural cells have not been previously investigated. I<italic>&#x003bd;</italic> o<italic>&#x003c1;</italic><italic>&#x003b4;</italic><italic>&#x0025b;</italic> to assess whether the expression of LOAD-dysregulated lncRNAs was altered by A&#x003b2; <italic>&#x0025b;&#x003be;&#x003c0;o&#x003c3;&#x003c5;&#x003c1;&#x0025b;</italic>, we treated differentiated hNSCs with 10<italic>&#x003bc;</italic>M of soluble A&#x003b2;<sub>42</sub> and then measured the expression of <italic>AD-linc1</italic>, <italic>AD-linc2</italic>, <italic>HAO2-AS</italic>, and <italic>EBF3-AS</italic> using qRT-PCR. We observed that 48&#x0200a;h exposure of A&#x003b2;<sub>42</sub> triggers the expression of the novel lincRNA overexpressed in LOAD, AD-linc1. As expected, exposure to A&#x003b2;<sub>42</sub> also induces activation of <italic>c-FOS</italic> [<xref rid="r55" ref-type="bibr">55</xref>] in differentiated neural cells. These data imply that accumulation of A&#x003b2;<sub>42</sub> in LOAD induces the expression of AD-linc1, which might contribute to A&#x003b2;<sub>42</sub> induced neurotoxicity.</p></sec></sec><sec id="sec0105"><title>DISCUSSION</title><p>The complex etiology of LOAD suggests that the pathology results from intricate interplay of genetic predisposition and environmental factors. This interplay is reflected in epigenomic and transcriptomic alteration of neural cells during disease progression [<xref rid="r56" ref-type="bibr">56&#x02013;58</xref>]. Transcriptome profiling is an important tool in studying complex disorders to identify end-stage alterations that converge from interaction of multiple genetic, epigenetic, and environmental factors. The intricate nature of contributing factors might be hard to identify without studying their end products of transcriptome alterations in the affected brain tissues. Historically, transcriptome profiling was performed using microarray technology with the major limitation of measuring only previously identified probes. Second major limitation of studying transcriptome is quality of RNA samples, particularly human variations, comorbidities, tissue type, and long PMIs. Recent advances in RNA sequencing technologies have greatly contributed to understand the extent and complexity of mammalian transcriptomes and to unravel molecular mechanisms involved in the pathogenesis of complex diseases.</p><p>In this study, we used RNAseq to profile the expression of coding and non-protein coding RNA transcripts in the hippocampus of 4 LOAD patients compared to 4 healthy age-matched control individuals. We identified known and novel RNA transcripts, including protein-coding genes, lincRNAs, and NATs to be dysregulated in the brain of LOAD patients. We validated sequencing data using qRT-PCR in a larger set of high quality, short PMI RNA samples and we confirmed dysregulation of candidate genes in other brain regions affected by the disease. Moreover, we demonstrated that expression of several lncRNAs dysregulated in LOAD is dependent on neuronal activity, further indicating their role in disease-related alteration in neuronal function. We found more than a hundred protein coding genes to be differentially expressed in LOAD and pathways analysis suggested alteration in neural communication and cerebral vasculature. According to the &#x0201c;two-hit vascular hypothesis&#x0201d; of AD [<xref rid="r59" ref-type="bibr">59</xref>], a vascular-related dysfunction represents the first hit in the etiology of the disease. This initial hit is the cause of neurovascular defects like blood-brain barrier (BBB) dysfunction and oligaemia, which have been repeatedly observed in LOAD patients, and which may be directly responsible for both neuronal dysfunction and alteration in A&#x003b2; production and clearance [<xref rid="r60" ref-type="bibr">60</xref>]. In healthy physiological conditions, the BBB protects the brain by regulating the entrance of blood-born molecules through the activity of specific transporters or receptors [<xref rid="r61" ref-type="bibr">61&#x02013;63</xref>]. Thus BBB breakdown and the uncontrolled trafficking of molecules, peptides, and cells from the blood to the brain and from the brain to the blood may participate in the activation of neuroinflammation and directly influence A&#x003b2; homeostasis in the brain [<xref rid="r64" ref-type="bibr">64</xref>]. The imbalance in A&#x003b2; homeostasis caused by the first hit culminates with the accumulation of A&#x003b2; in the brain and represents the second hit necessary for the progression of the pathology. When we mined our dataset looking for genes potentially implicated in both regulating vasculature function and A&#x003b2; homeostasis, our attention was caught by <italic>SERPINE1</italic>, which was among the most over-expressed protein-coding genes. <italic>SERPINE1</italic> codes for PAI-1, which is the main activator of the plasmin cascade and fibrinolysis. In the brain, PAI-1 is mainly produced by endothelial cells, but it is also present in astrocytes and pericytes [<xref rid="r65" ref-type="bibr">65</xref>]. Increased expression of SERPINE1 and impairment of the fibrinolytic cascade are associable with thrombotic conditions, stroke, artery disease, atherosclerosis, and diabetes [<xref rid="r66" ref-type="bibr">66</xref>]. Interestingly all these conditions have been reported by epidemiological studies to be risk factors for AD [<xref rid="r67" ref-type="bibr">67</xref>]. Moreover, increased expression of SERPINE1 has been observed in the brain of A&#x003b2;PP/PS1 transgenic mice and in the cortex of AD patients and knockout of SERPINE1 in A&#x003b2;PP/PS1 mice reduces the amounts of both soluble and insoluble A&#x003b2; and plaques in the&#x000a0;brain [<xref rid="r68" ref-type="bibr">68&#x02013;70</xref>]. In our study, using qRT-PCR we demonstrated robust overexpression of <italic>SERPINE1</italic> in AD brain regions that are characterized by A&#x003b2; accumulation during the pathogenesis of the disease, but not in non-affected regions like cerebellum. Our findings open the possibility that the increased expression of <italic>SERPINE1</italic> and the suppression of fibrinolysis may play a dual role in LOAD. First, it may lead to neurovascular dysfunction and second, it may cause impairment in amyloid clearance, thus resulting in increased A&#x003b2; levels. SERPINE1 overexpression in LOAD cases, as we reported here, and the crucial involvement of this protein in both the pathophysiology of cerebral vasculature and regulation of amyloid homeostasis strongly support the &#x0201c;two-hit vascular hypothesis&#x0201d; for AD.</p><p>Data generated in the past 10 years mostly from the&#x000a0;effort of two international research consortiums, the ENCODE and the FANTOM, demonstrated that the majority of the human genome is transcribed mostly in non-protein coding RNAs [<xref rid="r27" ref-type="bibr">27</xref>]. A clear functional classification of these RNA transcripts is still not available due to the paucity of functionally validated examples; however, ncRNAs can be classified by their length into short ncRNAs (&#x0003c;30 nt) and long ncRNAs (&#x0003e;200 nt). In the brain and nervous system, lncRNAs are particularly abundant [<xref rid="r71" ref-type="bibr">71</xref>], have cell-type and activity-dependent specificity of expression [<xref rid="r45" ref-type="bibr">45</xref>], and play fundamental roles in a variety of biological processes and diseases, including AD [<xref rid="r28" ref-type="bibr">28</xref>]. For instance, our previous works demonstrated the pivotal role of the antisense long ncRNA (lncRNA) <italic>BACE1-AS</italic> in the pathophysiology of LOAD [<xref rid="r14" ref-type="bibr">14, 72, 73</xref>]. Even thought catalogs of lncRNAs have been described in many human cell types and in multiple types of cancer [<xref rid="r74" ref-type="bibr">74</xref>], demonstrating the existence of cell-specific and disease-specific lncRNAs, a signature of lncRNAs for LOAD is still missing. We identified several annotated and non-annotated lncRNAs differentially expressed in LOAD hippocampi compared to control, thus providing for the first time a list of unexplored potential targets that could be involved in the pathogenesis of the disease. We went further to investigate the expression of four lncRNA candidates using qRT-PCR in a bigger cohort of brain samples. Interestingly, we noted clear changes in the expression of these lncRNAs not only in the hippocampus but also in the entorhinal cortex and superior frontal gyrus of LOAD patients. As a control for our study, we analyzed expression of these ncRNA in the cerebellum, a brain region only partially affected by the disease, and we could not detect any statistical changes in the expression of these four lncRNAs between patients and control samples. Interestingly all the four ncRNAs are enriched in the nuclear or chromatin compartment and the expression of three of them is triggered in response to neuronal activity, thus suggesting involvement of these ncRNAs in activity-dependent, nuclear-associated cellular processes. In cultured human neural cells, the expression of one of the discovered lincRNA, <italic>AD-linc1</italic>, is triggered by A&#x003b2;<sub>1&#x000a0;-&#x000a0;42</sub> exposure. These data suggest that the observed overexpression of <italic>AD-linc1</italic> in LOAD is due to A&#x003b2;<sub>1&#x000a0;-&#x000a0;42</sub> accumulation and open the possibility that <italic>AD-linc1</italic> is involved in amyloid-induced neurotoxicity. Alternations of activities of specific neuronal networks during AD are thought to be important contributors to the development and progression of the pathology, in part through regional vulnerability to A&#x003b2; deposition [<xref rid="r75" ref-type="bibr">75</xref>]. Differential expression of these lncRNAs in LOAD cases, tissue-specific pattern of expression and their nuclear localization suggest involvement of noncoding part of genome in complex disorders such as LOAD and warrant holistic approaches to consider these transcripts together with protein-coding genes in studies aim to understand pathological processes leading to LOAD.</p></sec><sec id="sec0110"><title>CONCLUSIONS</title><p>Our data demonstrate the existence of region specific transcriptomic changes in the brain of LOAD patients in protein and non-protein coding genes and represent an important resource of LOAD-specific transcriptomic changes that can help to better understand alterations in biological cellular pathways that contribute to the pathophysiology of AD.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><label>Supplementary File 1</label><caption><p>Brain samples information. Clinicopathological information of the LOAD and control brain samples utilized for RNAseq and qRT-PCR in the study.</p></caption><media xlink:href="jad-48-3-jad150398-s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><label>Supplementary File 2</label><caption><p>Gene expression profile of LOAD and control hippocampi. RNAseq data showing the expression of protein-coding genes (PCGs), long intergenic ncRNAs (lincRNAs) and antisense RNAs in the hippocampi of 4 LOAD patients and 4 controls.</p></caption><media xlink:href="jad-48-3-jad150398-s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><label>Supplementary File 3</label><caption><p>Genes differentially expressed in LOAD hippocampus. Differentially expressed protein-coding genes (PCGs), long intergenic ncRNAs (lincRNAs) and antisense RNAs in the hippocampi of 4 LOAD patients and 4 controls</p></caption><media xlink:href="jad-48-3-jad150398-s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><label>Supplementary File 4</label><caption><p>RNAseq and qRT-PCR correlation analysis. Pearson correlation analysis of log2 fold change differences from RNAseq and qRT-PCR data for 6 different protein coding genes, 6 lincRNAs and 6 AS RNA transcripts.</p></caption><media xlink:href="jad-48-3-jad150398-s004.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><label>Supplementary File 5</label><caption><p>Gene expression changes showing in vitro differentiation of human NSCs into a mixed population of neural cells. qRT-PCR analysis of the expression of the neural stem cells marker Nestin and different neuronal markers (NFH, DCX, &#x003b2;III-Tub) in RNA isolated from human NSCs differentiated for 21 days. On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene &#x003b2;-ACTIN. Gene expression is normalized to hNSCs.</p></caption><media xlink:href="jad-48-3-jad150398-s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><label>Supplementary File 6</label><caption><p>Expression of genes nearby LOAD-dysregulated lncRNAs upon KCl-induced depolarization of human neural cells. qRT-PCR analysis showing expression changes 1h post KCl stimulation of genes located nearby LOAD-dysregulated lncRNAs. EBF3, MGMT and Linc00959 are located nearby EBF3-AS. OGFRL1 is located nearby AD-linc2. On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene &#x003b2;-ACTIN. Gene expression is normalized to non-treated cells. Error bars are S.D.</p></caption><media xlink:href="jad-48-3-jad150398-s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S7"><label>Supplementary File 7</label><caption><p>qPCR Primers sequence.</p></caption><media xlink:href="jad-48-3-jad150398-s007.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by the US NIH NINDS R01NS081208-01A1 awarded to Mohammad Ali Faghihi. Dr. Magistri was supported by the fellowship for Prospective Researcher from the Swiss National Science Foundation, which covered the first year of his postdoctoral training.</p><p>Authors&#x02019; disclosures available online (<ext-link ext-link-type="uri" xlink:href="http://j-alz.com/manuscript-disclosures/15-0398r2">http://j-alz.com/manuscript-disclosures/15-0398r2</ext-link>).</p></ack><app-group><app><title>Appendix</title><supplementary-material content-type="local-data"><p>The supplementary material is available in the electronic version of this article: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3233/JAD-150398">http://dx.doi.org/10.3233/JAD-150398</ext-link>.</p></supplementary-material></app></app-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>LE</given-names></name><name><surname>Weuve</surname><given-names>J</given-names></name><name><surname>Scherr</surname><given-names>PA</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name></person-group><year>2013</year><article-title>Alzheimer disease in the United States (2010-2050) estimated using the 2010 census</article-title><source>Neurology</source><volume>80</volume><fpage>1778</fpage><lpage>1783</lpage><pub-id pub-id-type="pmid">23390181</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>DE</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><year>2011</year><article-title>The projected effect of risk factor reduction on Alzheimer&#x02019;s disease prevalence</article-title><source>Lancet Neurol</source><volume>10</volume><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">21775213</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Kanekiyo</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name></person-group><year>2013</year><article-title>Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy</article-title><source>Nat Rev Neurol</source><volume>9</volume><fpage>106</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">23296339</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Hamshere</surname><given-names>ML</given-names></name><name><surname>Pahwa</surname><given-names>JS</given-names></name><name><surname>Moskvina</surname><given-names>V</given-names></name><name><surname>Dowzell</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Stretton</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>AR</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Passmore</surname><given-names>PA</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>McGuinness</surname><given-names>B</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>N</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Schurmann</surname><given-names>B</given-names></name><name><surname>Heun</surname><given-names>R</given-names></name><name><surname>van den Bussche</surname><given-names>H</given-names></name><name><surname>Heuser</surname><given-names>I</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Frolich</surname><given-names>L</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Nowotny</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name><name><surname>Bass</surname><given-names>NJ</given-names></name><name><surname>Gurling</surname><given-names>H</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Gwilliam</surname><given-names>R</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Guerreiro</surname><given-names>R</given-names></name><name><surname>Muhleisen</surname><given-names>TW</given-names></name><name><surname>Nothen</surname><given-names>MM</given-names></name><name><surname>Moebus</surname><given-names>S</given-names></name><name><surname>Jockel</surname><given-names>KH</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Holmans</surname><given-names>PA</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>M</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name></person-group><year>2009</year><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x02019;s disease</article-title><source>Nat Genet</source><volume>41</volume><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">19734902</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Even</surname><given-names>G</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Zelenika</surname><given-names>D</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Tavernier</surname><given-names>B</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Fievet</surname><given-names>N</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>De Deyn</surname><given-names>P</given-names></name><name><surname>Mateo</surname><given-names>I</given-names></name><name><surname>Franck</surname><given-names>A</given-names></name><name><surname>Helisalmi</surname><given-names>S</given-names></name><name><surname>Porcellini</surname><given-names>E</given-names></name><name><surname>Hanon</surname><given-names>O</given-names></name><name><surname>de Pancorbo</surname><given-names>MM</given-names></name><name><surname>Lendon</surname><given-names>C</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Jaillard</surname><given-names>C</given-names></name><name><surname>Leveillard</surname><given-names>T</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Bosco</surname><given-names>P</given-names></name><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Panza</surname><given-names>F</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Bossu</surname><given-names>P</given-names></name><name><surname>Piccardi</surname><given-names>P</given-names></name><name><surname>Annoni</surname><given-names>G</given-names></name><name><surname>Seripa</surname><given-names>D</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Blanche</surname><given-names>H</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Alperovitch</surname><given-names>A</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name></person-group><year>2009</year><article-title>Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x02019;s disease</article-title><source>Nat Genet</source><volume>41</volume><fpage>1094</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">19734903</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Hamshere</surname><given-names>ML</given-names></name><name><surname>Pahwa</surname><given-names>JS</given-names></name><name><surname>Moskvina</surname><given-names>V</given-names></name><name><surname>Dowzell</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Stretton</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Richards</surname><given-names>A</given-names></name><name><surname>Ivanov</surname><given-names>D</given-names></name><name><surname>Widdowson</surname><given-names>C</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Passmore</surname><given-names>PA</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>McGuinness</surname><given-names>B</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Beaumont</surname><given-names>H</given-names></name><name><surname>Warden</surname><given-names>D</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><name><surname>Vardy</surname><given-names>ER</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Ruther</surname><given-names>E</given-names></name><name><surname>Schurmann</surname><given-names>B</given-names></name><name><surname>Heun</surname><given-names>R</given-names></name><name><surname>Kolsch</surname><given-names>H</given-names></name><name><surname>van den Bussche</surname><given-names>H</given-names></name><name><surname>Heuser</surname><given-names>I</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Frolich</surname><given-names>L</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Gallacher</surname><given-names>J</given-names></name><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Giegling</surname><given-names>I</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Nowotny</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name><name><surname>Bass</surname><given-names>NJ</given-names></name><name><surname>Gurling</surname><given-names>H</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Gwilliam</surname><given-names>R</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Guerreiro</surname><given-names>R</given-names></name><name><surname>Muhleisen</surname><given-names>TW</given-names></name><name><surname>Nothen</surname><given-names>MM</given-names></name><name><surname>Moebus</surname><given-names>S</given-names></name><name><surname>Jockel</surname><given-names>KH</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Sando</surname><given-names>SB</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name><name><surname>Barcikowska</surname><given-names>M</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name><surname>Lopez</surname><given-names>O</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Epelbaum</surname><given-names>J</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Alperovitch</surname><given-names>A</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Feulner</surname><given-names>TM</given-names></name><name><surname>Friedrich</surname><given-names>P</given-names></name><name><surname>Riehle</surname><given-names>C</given-names></name><name><surname>Krawczak</surname><given-names>M</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Mayhaus</surname><given-names>M</given-names></name><name><surname>Nicolhaus</surname><given-names>S</given-names></name><name><surname>Wagenpfeil</surname><given-names>S</given-names></name><name><surname>Steinberg</surname><given-names>S</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Snaedal</surname><given-names>J</given-names></name><name><surname>Bjornsson</surname><given-names>S</given-names></name><name><surname>Jonsson</surname><given-names>PV</given-names></name><name><surname>Chouraki</surname><given-names>V</given-names></name><name><surname>Genier-Boley</surname><given-names>B</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Zelenika</surname><given-names>D</given-names></name><name><surname>Delepine</surname><given-names>M</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Mateo</surname><given-names>I</given-names></name><name><surname>Frank-Garcia</surname><given-names>A</given-names></name><name><surname>Porcellini</surname><given-names>E</given-names></name><name><surname>Hanon</surname><given-names>O</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Bosco</surname><given-names>P</given-names></name><name><surname>Siciliano</surname><given-names>G</given-names></name><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Panza</surname><given-names>F</given-names></name><name><surname>Solfrizzi</surname><given-names>V</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Bossu</surname><given-names>P</given-names></name><name><surname>Piccardi</surname><given-names>P</given-names></name><name><surname>Arosio</surname><given-names>B</given-names></name><name><surname>Annoni</surname><given-names>G</given-names></name><name><surname>Seripa</surname><given-names>D</given-names></name><name><surname>Pilotto</surname><given-names>A</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Holmans</surname><given-names>PA</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>M</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name></person-group><year>2011</year><article-title>Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x02019;s disease</article-title><source>Nat Genet</source><volume>43</volume><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">21460840</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naj</surname><given-names>AC</given-names></name><name><surname>Jun</surname><given-names>G</given-names></name><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Vardarajan</surname><given-names>BN</given-names></name><name><surname>Buros</surname><given-names>J</given-names></name><name><surname>Gallins</surname><given-names>PJ</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Jarvik</surname><given-names>GP</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Evans</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Ertekin-Taner</surname><given-names>N</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Nowotny</surname><given-names>P</given-names></name><name><surname>Kramer</surname><given-names>P</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Huentelman</surname><given-names>MJ</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Barmada</surname><given-names>MM</given-names></name><name><surname>Demirci</surname><given-names>FY</given-names></name><name><surname>Baldwin</surname><given-names>CT</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><name><surname>Beach</surname><given-names>T</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Bowen</surname><given-names>JD</given-names></name><name><surname>Boxer</surname><given-names>A</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Carroll</surname><given-names>SL</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Clark</surname><given-names>DG</given-names></name><name><surname>Corneveaux</surname><given-names>J</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Diaz-Arrastia</surname><given-names>R</given-names></name><name><surname>Dick</surname><given-names>M</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Ellis</surname><given-names>WG</given-names></name><name><surname>Faber</surname><given-names>KM</given-names></name><name><surname>Fallon</surname><given-names>KB</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Ganguli</surname><given-names>M</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Giordani</surname><given-names>B</given-names></name><name><surname>Glass</surname><given-names>JD</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Harrell</surname><given-names>LE</given-names></name><name><surname>Head</surname><given-names>E</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Hulette</surname><given-names>CM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jicha</surname><given-names>GA</given-names></name><name><surname>Jin</surname><given-names>LW</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Karlawish</surname><given-names>J</given-names></name><name><surname>Karydas</surname><given-names>A</given-names></name><name><surname>Kaye</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Lieberman</surname><given-names>AP</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Mack</surname><given-names>WJ</given-names></name><name><surname>Marson</surname><given-names>DC</given-names></name><name><surname>Martiniuk</surname><given-names>F</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>McCormick</surname><given-names>WC</given-names></name><name><surname>McCurry</surname><given-names>SM</given-names></name><name><surname>McDavid</surname><given-names>AN</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>Mesulam</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Perl</surname><given-names>DP</given-names></name><name><surname>Peskind</surname><given-names>E</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Poon</surname><given-names>WW</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Rajbhandary</surname><given-names>RA</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Rosenberg</surname><given-names>RN</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Seeley</surname><given-names>W</given-names></name><name><surname>Shelanski</surname><given-names>ML</given-names></name><name><surname>Slifer</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Sonnen</surname><given-names>JA</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Woltjer</surname><given-names>RL</given-names></name><name><surname>Cantwell</surname><given-names>LB</given-names></name><name><surname>Dombroski</surname><given-names>BA</given-names></name><name><surname>Beekly</surname><given-names>D</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Tsuang</surname><given-names>DW</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name></person-group><year>2011</year><article-title>Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x02019;s disease</article-title><source>Nat Genet</source><volume>43</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">21460841</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Ibrahim-Verbaas</surname><given-names>CA</given-names></name><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Naj</surname><given-names>AC</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Bellenguez</surname><given-names>C</given-names></name><name><surname>DeStafano</surname><given-names>AL</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Grenier-Boley</surname><given-names>B</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Thorton-Wells</surname><given-names>TA</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Chouraki</surname><given-names>V</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Zelenika</surname><given-names>D</given-names></name><name><surname>Vardarajan</surname><given-names>BN</given-names></name><name><surname>Kamatani</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>CF</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Kunkle</surname><given-names>B</given-names></name><name><surname>Dunstan</surname><given-names>ML</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Bihoreau</surname><given-names>MT</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Johnston</surname><given-names>JA</given-names></name><name><surname>Evans</surname><given-names>D</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Moron</surname><given-names>FJ</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Fievet</surname><given-names>N</given-names></name><name><surname>Huentelman</surname><given-names>MW</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Keller</surname><given-names>L</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P</given-names></name><name><surname>McGuiness</surname><given-names>B</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Green</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Gallacher</surname><given-names>J</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><name><surname>Tsuang</surname><given-names>DW</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Bossu</surname><given-names>P</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>F</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Deniz Naranjo</surname><given-names>MC</given-names></name><name><surname>Bosco</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Matthews</surname><given-names>F</given-names></name><name><surname>Moebus</surname><given-names>S</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Del Zompo</surname><given-names>M</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Pilotto</surname><given-names>A</given-names></name><name><surname>Bullido</surname><given-names>M</given-names></name><name><surname>Panza</surname><given-names>F</given-names></name><name><surname>Caffarra</surname><given-names>P</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Mayhaus</surname><given-names>M</given-names></name><name><surname>Lannefelt</surname><given-names>L</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Pichler</surname><given-names>S</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Beekly</surname><given-names>D</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Valladares</surname><given-names>O</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Hamilton-Nelson</surname><given-names>KL</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Razquin</surname><given-names>C</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><name><surname>Mateo</surname><given-names>I</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Faber</surname><given-names>KM</given-names></name><name><surname>Jonsson</surname><given-names>PV</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>MC</given-names></name><name><surname>Cantwell</surname><given-names>LB</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Mosley</surname><given-names>TH</given-names><suffix>Jr</suffix></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>de Bruijn</surname><given-names>RF</given-names></name><name><surname>Passmore</surname><given-names>P</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Powell</surname><given-names>JF</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Hiltuenen</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Nothen</surname><given-names>MM</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Holmans</surname><given-names>PA</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Moskvina</surname><given-names>V</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name></person-group><year>2013</year><article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x02019;s disease</article-title><source>Nat Genet</source><volume>45</volume><fpage>1452</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">24162737</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniilidou</surname><given-names>M</given-names></name><name><surname>Koutroumani</surname><given-names>M</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name></person-group><year>2011</year><article-title>Epigenetic mechanisms in Alzheimer&#x02019;s disease</article-title><source>Curr Med Chem</source><volume>18</volume><fpage>1751</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">21466476</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper-Knock</surname><given-names>J</given-names></name><name><surname>Kirby</surname><given-names>J</given-names></name><name><surname>Ferraiuolo</surname><given-names>L</given-names></name><name><surname>Heath</surname><given-names>PR</given-names></name><name><surname>Rattray</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name></person-group><year>2012</year><article-title>Gene expression profiling in human neurodegenerative disease</article-title><source>Nat Rev Neurol</source><volume>8</volume><fpage>518</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">22890216</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handel</surname><given-names>AE</given-names></name><name><surname>Disanto</surname><given-names>G</given-names></name><name><surname>Ramagopalan</surname><given-names>SV</given-names></name></person-group><year>2013</year><article-title>Next-generation sequencing in understanding complex neurological disease</article-title><source>Expert Rev Neurother</source><volume>13</volume><fpage>215</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">23368808</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozsolak</surname><given-names>F</given-names></name><name><surname>Milos</surname><given-names>PM</given-names></name></person-group><year>2011</year><article-title>RNA sequencing: Advances, challenges and opportunities</article-title><source>Nat Rev Genet</source><volume>12</volume><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">21191423</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>GT</given-names></name><name><surname>Janitz</surname><given-names>M</given-names></name><name><surname>Kril</surname><given-names>JJ</given-names></name></person-group><year>2011</year><article-title>Understanding the pathogenesis of Alzheimer&#x02019;s disease: Will RNA-Seq realize the promise of transcriptomics?</article-title><source>J Neurochem</source><volume>116</volume><fpage>937</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">21175619</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faghihi</surname><given-names>MA</given-names></name><name><surname>Modarresi</surname><given-names>F</given-names></name><name><surname>Khalil</surname><given-names>AM</given-names></name><name><surname>Wood</surname><given-names>DE</given-names></name><name><surname>Sahagan</surname><given-names>BG</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>St Laurent</surname><given-names>G</given-names><suffix>3rd</suffix></name><name><surname>Kenny</surname><given-names>PJ</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year>2008</year><article-title>Expression of a noncoding RNA is elevated in Alzheimer&#x02019;s disease and drives rapid feed-forward regulation of beta-secretase</article-title><source>Nat Med</source><volume>14</volume><fpage>723</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">18587408</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>McKeel</surname><given-names>D</given-names></name><name><surname>Sumi</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>BJ</given-names></name><name><surname>Brownlee</surname><given-names>LM</given-names></name><name><surname>Vogel</surname><given-names>FS</given-names></name><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>van Belle</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name></person-group><year>1991</year><article-title>The Consortium to Establish a Registry for Alzheimer&#x02019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x02019;s disease</article-title><source>Neurology</source><volume>41</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">2011243</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><year>1991</year><article-title>Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections</article-title><source>Brain Pathol</source><volume>1</volume><fpage>213</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">1669710</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><year>1997</year><article-title>Consensus recommendations for the postmortem diagnosis of Alzheimer&#x02019;s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x02019;s Disease</article-title><source>Neurobiol Aging</source><volume>18</volume><fpage>S1</fpage><lpage>S2</lpage><pub-id pub-id-type="pmid">9330978</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>F</given-names></name><name><surname>Breitling</surname><given-names>R</given-names></name><name><surname>McEntee</surname><given-names>CW</given-names></name><name><surname>Wittner</surname><given-names>BS</given-names></name><name><surname>Nemhauser</surname><given-names>JL</given-names></name><name><surname>Chory</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis</article-title><source>Bioinformatics</source><volume>22</volume><fpage>2825</fpage><lpage>2827</lpage><pub-id pub-id-type="pmid">16982708</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>M</given-names></name><name><surname>Vidaurre</surname><given-names>I</given-names></name><name><surname>Geffin</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Maturing neurons are selectively sensitive to human immunodeficiency virus type 1 exposure in differentiating human neuroepithelial progenitor cell cultures</article-title><source>J Neurovirol</source><volume>12</volume><fpage>333</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">17065126</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year>2009</year><article-title>TopHat: Discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">19289445</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>G</given-names></name><name><surname>van Baren</surname><given-names>MJ</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Wold</surname><given-names>BJ</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year>2010</year><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title><source>Nat Biotechnol</source><volume>28</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">20436464</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kelley</surname><given-names>DR</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year>2012</year><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title><source>Nat Protoc</source><volume>7</volume><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Dasari</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kocher</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year>2013</year><article-title>CPAT: Coding-Potential Assessment Tool using an alignment-free logistic regression model</article-title><source>Nucleic Acids Res</source><volume>41</volume><fpage>e74</fpage><pub-id pub-id-type="pmid">23335781</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname><given-names>R</given-names></name><name><surname>Domrachev</surname><given-names>M</given-names></name><name><surname>Lash</surname><given-names>AE</given-names></name></person-group><year>2002</year><article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title><source>Nucleic Acids Res</source><volume>30</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">11752295</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Wilhite</surname><given-names>SE</given-names></name><name><surname>Ledoux</surname><given-names>P</given-names></name><name><surname>Evangelista</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>IF</given-names></name><name><surname>Tomashevsky</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>KA</given-names></name><name><surname>Phillippy</surname><given-names>KH</given-names></name><name><surname>Sherman</surname><given-names>PM</given-names></name><name><surname>Holko</surname><given-names>M</given-names></name><name><surname>Yefanov</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Robertson</surname><given-names>CL</given-names></name><name><surname>Serova</surname><given-names>N</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Soboleva</surname><given-names>A</given-names></name></person-group><year>2013</year><article-title>NCBI GEO: Archive for functional genomics data sets&#x02013;update</article-title><source>Nucleic Acids Res</source><volume>41</volume><fpage>D991</fpage><lpage>D995</lpage><pub-id pub-id-type="pmid">23193258</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitling</surname><given-names>R</given-names></name><name><surname>Armengaud</surname><given-names>P</given-names></name><name><surname>Amtmann</surname><given-names>A</given-names></name><name><surname>Herzyk</surname><given-names>P</given-names></name></person-group><year>2004</year><article-title>Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments</article-title><source>FEBS Lett</source><volume>573</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15327980</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>M</given-names></name><name><surname>Hutter-Paier</surname><given-names>B</given-names></name><name><surname>Wietzorrek</surname><given-names>G</given-names></name><name><surname>Windisch</surname><given-names>M</given-names></name><name><surname>Humpel</surname><given-names>C</given-names></name><name><surname>Knaus</surname><given-names>HG</given-names></name><name><surname>Marksteiner</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations</article-title><source>Brain Res</source><volume>1143</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">17328871</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>MF</given-names></name><name><surname>Mazurek</surname><given-names>MF</given-names></name></person-group><year>1987</year><article-title>Substance P-like immunoreactivity is reduced in Alzheimer&#x02019;s disease cerebral cortex</article-title><source>Neurology</source><volume>37</volume><fpage>1205</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">2439949</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melchor</surname><given-names>JP</given-names></name><name><surname>Pawlak</surname><given-names>R</given-names></name><name><surname>Strickland</surname><given-names>S</given-names></name></person-group><year>2003</year><article-title>The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration</article-title><source>J Neurosci</source><volume>23</volume><fpage>8867</fpage><lpage>8871</lpage><pub-id pub-id-type="pmid">14523088</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name></person-group><year>2014</year><article-title>Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer&#x02019;s disease</article-title><source>Exp Gerontol</source><volume>60</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">25304332</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>Evoking plasmin for beta-amyloid clearance</article-title><source>Cell Res</source><volume>18</volume><fpage>803</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">18679173</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magistri</surname><given-names>M</given-names></name><name><surname>Faghihi</surname><given-names>MA</given-names></name><name><surname>St Laurent</surname><given-names>G</given-names><suffix>3rd</suffix></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year>2012</year><article-title>Regulation of chromatin structure by long noncoding RNAs: Focus on natural antisense transcripts</article-title><source>Trends Genet</source><volume>28</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">22541732</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faghihi</surname><given-names>MA</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year>2009</year><article-title>Regulatory roles of natural antisense transcripts</article-title><source>Nat Rev Mol Cell Biol</source><volume>10</volume><fpage>637</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">19638999</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastori</surname><given-names>C</given-names></name><name><surname>Magistri</surname><given-names>M</given-names></name><name><surname>Napoli</surname><given-names>S</given-names></name><name><surname>Carbone</surname><given-names>GM</given-names></name><name><surname>Catapano</surname><given-names>CV</given-names></name></person-group><year>2010</year><article-title>Small RNA-directed transcriptional control: New insights into mechanisms and therapeutic applications</article-title><source>Cell Cycle</source><volume>9</volume><fpage>2353</fpage><lpage>2362</lpage><pub-id pub-id-type="pmid">20519954</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velmeshev</surname><given-names>D</given-names></name><name><surname>Magistri</surname><given-names>M</given-names></name><name><surname>Faghihi</surname><given-names>MA</given-names></name></person-group><year>2013</year><article-title>Expression of non-protein-coding antisense RNAs in genomic regions related to autism spectrum disorders</article-title><source>Mol Autism</source><volume>4</volume><fpage>32</fpage><pub-id pub-id-type="pmid">24007600</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>French</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>MF</given-names></name><name><surname>Feldser</surname><given-names>D</given-names></name><name><surname>Huarte</surname><given-names>M</given-names></name><name><surname>Zuk</surname><given-names>O</given-names></name><name><surname>Carey</surname><given-names>BW</given-names></name><name><surname>Cassady</surname><given-names>JP</given-names></name><name><surname>Cabili</surname><given-names>MN</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><year>2009</year><article-title>Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals</article-title><source>Nature</source><volume>458</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">19182780</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>AM</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Huarte</surname><given-names>M</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Raj</surname><given-names>A</given-names></name><name><surname>Rivea Morales</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>K</given-names></name><name><surname>Presser</surname><given-names>A</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>van Oudenaarden</surname><given-names>A</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name></person-group><year>2009</year><article-title>Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression</article-title><source>Proc Natl Acad Sci U S A</source><volume>106</volume><fpage>11667</fpage><lpage>11672</lpage><pub-id pub-id-type="pmid">19571010</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><year>2011</year><article-title>Molecular mechanisms of long noncoding RNAs</article-title><source>Mol Cell</source><volume>43</volume><fpage>904</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">21925379</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>F</given-names></name><name><surname>Orom</surname><given-names>UA</given-names></name><name><surname>Cesaroni</surname><given-names>M</given-names></name><name><surname>Beringer</surname><given-names>M</given-names></name><name><surname>Taatjes</surname><given-names>DJ</given-names></name><name><surname>Blobel</surname><given-names>GA</given-names></name><name><surname>Shiekhattar</surname><given-names>R</given-names></name></person-group><year>2013</year><article-title>Activating RNAs associate with Mediator to enhance chromatin architecture and transcription</article-title><source>Nature</source><volume>494</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">23417068</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orom</surname><given-names>UA</given-names></name><name><surname>Derrien</surname><given-names>T</given-names></name><name><surname>Beringer</surname><given-names>M</given-names></name><name><surname>Gumireddy</surname><given-names>K</given-names></name><name><surname>Gardini</surname><given-names>A</given-names></name><name><surname>Bussotti</surname><given-names>G</given-names></name><name><surname>Lai</surname><given-names>F</given-names></name><name><surname>Zytnicki</surname><given-names>M</given-names></name><name><surname>Notredame</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Guigo</surname><given-names>R</given-names></name><name><surname>Shiekhattar</surname><given-names>R</given-names></name></person-group><year>2010</year><article-title>Long noncoding RNAs with enhancer-like function in human cells</article-title><source>Cell</source><volume>143</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">20887892</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Notani</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Tanasa</surname><given-names>B</given-names></name><name><surname>Nunez</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Merkurjev</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ohgi</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name></person-group><year>2013</year><article-title>Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation</article-title><source>Nature</source><volume>498</volume><fpage>516</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">23728302</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Manor</surname><given-names>O</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Mosammaparast</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><year>2010</year><article-title>Long noncoding RNA as modular scaffold of histone modification complexes</article-title><source>Science</source><volume>329</volume><fpage>689</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">20616235</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Donaghey</surname><given-names>J</given-names></name><name><surname>Carey</surname><given-names>BW</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Grenier</surname><given-names>JK</given-names></name><name><surname>Munson</surname><given-names>G</given-names></name><name><surname>Young</surname><given-names>G</given-names></name><name><surname>Lucas</surname><given-names>AB</given-names></name><name><surname>Ach</surname><given-names>R</given-names></name><name><surname>Bruhn</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><year>2011</year><article-title>lincRNAs act in the circuitry controlling pluripotency and differentiation</article-title><source>Nature</source><volume>477</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">21874018</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Ruscio</surname><given-names>A</given-names></name><name><surname>Ebralidze</surname><given-names>AK</given-names></name><name><surname>Benoukraf</surname><given-names>T</given-names></name><name><surname>Amabile</surname><given-names>G</given-names></name><name><surname>Goff</surname><given-names>LA</given-names></name><name><surname>Terragni</surname><given-names>J</given-names></name><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>De Figueiredo Pontes</surname><given-names>LL</given-names></name><name><surname>Alberich-Jorda</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>D&#x02019;Alo</surname><given-names>F</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name><name><surname>Leone</surname><given-names>G</given-names></name><name><surname>Ebralidze</surname><given-names>KK</given-names></name><name><surname>Pradhan</surname><given-names>S</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year>2013</year><article-title>DNMT1-interacting RNAs block gene-specific DNA methylation</article-title><source>Nature</source><volume>503</volume><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">24107992</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>G</given-names></name><name><surname>Briggs</surname><given-names>JA</given-names></name><name><surname>Vanichkina</surname><given-names>DP</given-names></name><name><surname>Poth</surname><given-names>EM</given-names></name><name><surname>Beveridge</surname><given-names>NJ</given-names></name><name><surname>Ratnu</surname><given-names>VS</given-names></name><name><surname>Nayler</surname><given-names>SP</given-names></name><name><surname>Nones</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Bredy</surname><given-names>TW</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Taft</surname><given-names>RJ</given-names></name><name><surname>Cairns</surname><given-names>MJ</given-names></name><name><surname>Blackshaw</surname><given-names>S</given-names></name><name><surname>Wolvetang</surname><given-names>EJ</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group><year>2013</year><article-title>The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing</article-title><source>Mol Psychiatry</source><volume>19</volume><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">23628989</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Hemberg</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>JM</given-names></name><name><surname>Costa</surname><given-names>AM</given-names></name><name><surname>Bear</surname><given-names>DM</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Harmin</surname><given-names>DA</given-names></name><name><surname>Laptewicz</surname><given-names>M</given-names></name><name><surname>Barbara-Haley</surname><given-names>K</given-names></name><name><surname>Kuersten</surname><given-names>S</given-names></name><name><surname>Markenscoff-Papadimitriou</surname><given-names>E</given-names></name><name><surname>Kuhl</surname><given-names>D</given-names></name><name><surname>Bito</surname><given-names>H</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Kreiman</surname><given-names>G</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group><year>2010</year><article-title>Widespread transcription at neuronal activity-regulated enhancers</article-title><source>Nature</source><volume>465</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">20393465</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gritti</surname><given-names>A</given-names></name><name><surname>Parati</surname><given-names>EA</given-names></name><name><surname>Cova</surname><given-names>L</given-names></name><name><surname>Frolichsthal</surname><given-names>P</given-names></name><name><surname>Galli</surname><given-names>R</given-names></name><name><surname>Wanke</surname><given-names>E</given-names></name><name><surname>Faravelli</surname><given-names>L</given-names></name><name><surname>Morassutti</surname><given-names>DJ</given-names></name><name><surname>Roisen</surname><given-names>F</given-names></name><name><surname>Nickel</surname><given-names>DD</given-names></name><name><surname>Vescovi</surname><given-names>AL</given-names></name></person-group><year>1996</year><article-title>Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor</article-title><source>J Neurosci</source><volume>16</volume><fpage>1091</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">8558238</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tropepe</surname><given-names>V</given-names></name><name><surname>Sibilia</surname><given-names>M</given-names></name><name><surname>Ciruna</surname><given-names>BG</given-names></name><name><surname>Rossant</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>EF</given-names></name><name><surname>van der Kooy</surname><given-names>D</given-names></name></person-group><year>1999</year><article-title>Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon</article-title><source>Dev Biol</source><volume>208</volume><fpage>166</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10075850</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>C</given-names></name><name><surname>Nurnberg</surname><given-names>ST</given-names></name><name><surname>Jin</surname><given-names>KK</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>CJ</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Chien</surname><given-names>HC</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>PS</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>CP</given-names></name></person-group><year>2014</year><article-title>A long noncoding RNA protects the heart from pathological hypertrophy</article-title><source>Nature</source><volume>514</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">25119045</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakhotia</surname><given-names>SC</given-names></name></person-group><year>2012</year><article-title>Long non-coding RNAs coordinate cellular responses to stress</article-title><source>Wiley Interdiscip Rev RNA</source><volume>3</volume><fpage>779</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">22976942</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozgur</surname><given-names>E</given-names></name><name><surname>Mert</surname><given-names>U</given-names></name><name><surname>Isin</surname><given-names>M</given-names></name><name><surname>Okutan</surname><given-names>M</given-names></name><name><surname>Dalay</surname><given-names>N</given-names></name><name><surname>Gezer</surname><given-names>U</given-names></name></person-group><year>2013</year><article-title>Differential expression of long non-coding RNAs during genotoxic stress-induced apoptosis in HeLa and MCF-7 cells</article-title><source>Clin Exp Med</source><volume>13</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">22487937</pub-id></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massone</surname><given-names>S</given-names></name><name><surname>Ciarlo</surname><given-names>E</given-names></name><name><surname>Vella</surname><given-names>S</given-names></name><name><surname>Nizzari</surname><given-names>M</given-names></name><name><surname>Florio</surname><given-names>T</given-names></name><name><surname>Russo</surname><given-names>C</given-names></name><name><surname>Cancedda</surname><given-names>R</given-names></name><name><surname>Pagano</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title>NDM29, a RNA polymerase III-dependent non coding RNA, promotes amyloidogenic processing of APP and amyloid beta secretion</article-title><source>Biochim Biophys Acta</source><volume>1823</volume><fpage>1170</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">22580042</pub-id></element-citation></ref><ref id="r53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><year>2014</year><article-title>Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1AS expression</article-title><source>Mol Med Rep</source><volume>10</volume><fpage>1275</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">24970022</pub-id></element-citation></ref><ref id="r54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>MJ</given-names></name><name><surname>Abdelmohsen</surname><given-names>K</given-names></name><name><surname>Hutchison</surname><given-names>ER</given-names></name><name><surname>Mitchell</surname><given-names>SJ</given-names></name><name><surname>Grammatikakis</surname><given-names>I</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Noh</surname><given-names>JH</given-names></name><name><surname>Martindale</surname><given-names>JL</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>EK</given-names></name><name><surname>Faghihi</surname><given-names>MA</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>Perrone-Bizzozero</surname><given-names>N</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>de Cabo</surname><given-names>R</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name></person-group><year>2014</year><article-title>HuD regulates coding and noncoding RNA to induce APP&#x02013;&#x0003e;Abeta processing</article-title><source>Cell Rep</source><volume>7</volume><fpage>1401</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">24857657</pub-id></element-citation></ref><ref id="r55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillardon</surname><given-names>F</given-names></name><name><surname>Skutella</surname><given-names>T</given-names></name><name><surname>Uhlmann</surname><given-names>E</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Behl</surname><given-names>C</given-names></name></person-group><year>1996</year><article-title>Activation of c-Fos contributes to amyloid beta-peptide-induced neurotoxicity</article-title><source>Brain Res</source><volume>706</volume><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">8720507</pub-id></element-citation></ref><ref id="r56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastroeni</surname><given-names>D</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><name><surname>Delvaux</surname><given-names>E</given-names></name><name><surname>Whiteside</surname><given-names>C</given-names></name><name><surname>Coleman</surname><given-names>PD</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name></person-group><year>2010</year><article-title>Epigenetic changes in Alzheimer&#x02019;s disease: Decrements in DNA methylation</article-title><source>Neurobiol Aging</source><volume>31</volume><fpage>2025</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">19117641</pub-id></element-citation></ref><ref id="r57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahiri</surname><given-names>DK</given-names></name><name><surname>Maloney</surname><given-names>B</given-names></name></person-group><year>2010</year><article-title>The &#x0201c;LEARn&#x0201d; (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer&#x02019;s disease, and proposes remedial steps</article-title><source>Exp Gerontol</source><volume>45</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">20064601</pub-id></element-citation></ref><ref id="r58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Oelze</surname><given-names>B</given-names></name><name><surname>Schumacher</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>Age-specific epigenetic drift in late-onset Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><volume>3</volume><fpage>e2698</fpage><pub-id pub-id-type="pmid">18628954</pub-id></element-citation></ref><ref id="r59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><year>2011</year><article-title>Neurovascular pathways to neurodegeneration in Alzheimer&#x02019;s disease and other disorders</article-title><source>Nat Rev Neurosci</source><volume>12</volume><fpage>723</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">22048062</pub-id></element-citation></ref><ref id="r60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagare</surname><given-names>AP</given-names></name><name><surname>Bell</surname><given-names>RD</given-names></name><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><year>2013</year><article-title>Neurovascular defects and faulty amyloid-beta vascular clearance in Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis</source><volume>33</volume><issue>Suppl 1</issue><fpage>S87</fpage><lpage>S100</lpage><pub-id pub-id-type="pmid">22751174</pub-id></element-citation></ref><ref id="r61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>BV</given-names></name><name><surname>Begley</surname><given-names>DJ</given-names></name><name><surname>Chain-Eliash</surname><given-names>DG</given-names></name></person-group><year>1985</year><article-title>Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine)</article-title><source>Brain Res</source><volume>336</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">3891014</pub-id></element-citation></ref><ref id="r62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><year>1995</year><article-title>Cerebrovascular permeability to peptides: Manipulations of transport systems at the blood-brain barrier</article-title><source>Pharm Res</source><volume>12</volume><fpage>1395</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">8584471</pub-id></element-citation></ref><ref id="r63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>BV</given-names></name><name><surname>Lipovac</surname><given-names>MN</given-names></name><name><surname>Begley</surname><given-names>DJ</given-names></name><name><surname>Davson</surname><given-names>H</given-names></name><name><surname>Rakic</surname><given-names>L</given-names></name></person-group><year>1987</year><article-title>Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain</article-title><source>J Neurochem</source><volume>49</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">3585338</pub-id></element-citation></ref><ref id="r64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>F</given-names></name><name><surname>Sousa</surname><given-names>JC</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Palha</surname><given-names>JA</given-names></name></person-group><year>2013</year><article-title>Blood-brain-barriers in aging and in Alzheimer&#x02019;s disease</article-title><source>Mol Neurodegener</source><volume>8</volume><fpage>38</fpage><pub-id pub-id-type="pmid">24148264</pub-id></element-citation></ref><ref id="r65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Tran</surname><given-names>ND</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Fisher</surname><given-names>MJ</given-names></name></person-group><year>2006</year><article-title>Brain endothelial hemostasis regulation by pericytes</article-title><source>J Cereb Blood Flow Metab</source><volume>26</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">16015279</pub-id></element-citation></ref><ref id="r66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name><name><surname>Incalzi</surname><given-names>RA</given-names></name></person-group><year>2010</year><article-title>Plasminogen activator inhibitor-1 (PAI-1): A key factor linking fibrinolysis and age-related subclinical and clinical conditions</article-title><source>Cardiovasc Ther</source><volume>28</volume><fpage>e72</fpage><lpage>e91</lpage><pub-id pub-id-type="pmid">20626406</pub-id></element-citation></ref><ref id="r67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>JC</given-names></name></person-group><year>2002</year><article-title>Alzheimer disease as a vascular disorder: Nosological evidence</article-title><source>Stroke</source><volume>33</volume><fpage>1152</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">11935076</pub-id></element-citation></ref><ref id="r68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>RM</given-names></name><name><surname>van Groen</surname><given-names>T</given-names></name><name><surname>Katre</surname><given-names>A</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Kadisha</surname><given-names>I</given-names></name><name><surname>Ballinger</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Carroll</surname><given-names>SL</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><year>2011</year><article-title>Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><volume>32</volume><fpage>1079</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">19604604</pub-id></element-citation></ref><ref id="r69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>JS</given-names></name><name><surname>Comery</surname><given-names>TA</given-names></name><name><surname>Martone</surname><given-names>RL</given-names></name><name><surname>Elokdah</surname><given-names>H</given-names></name><name><surname>Crandall</surname><given-names>DL</given-names></name><name><surname>Oganesian</surname><given-names>A</given-names></name><name><surname>Aschmies</surname><given-names>S</given-names></name><name><surname>Kirksey</surname><given-names>Y</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Atchison</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name><name><surname>Zaleska</surname><given-names>MM</given-names></name><name><surname>Das</surname><given-names>I</given-names></name><name><surname>Arias</surname><given-names>RL</given-names></name><name><surname>Bard</surname><given-names>J</given-names></name><name><surname>Riddell</surname><given-names>D</given-names></name><name><surname>Gardell</surname><given-names>SJ</given-names></name><name><surname>Abou-Gharbia</surname><given-names>M</given-names></name><name><surname>Robichaud</surname><given-names>A</given-names></name><name><surname>Magolda</surname><given-names>R</given-names></name><name><surname>Vlasuk</surname><given-names>GP</given-names></name><name><surname>Bjornsson</surname><given-names>T</given-names></name><name><surname>Reinhart</surname><given-names>PH</given-names></name><name><surname>Pangalos</surname><given-names>MN</given-names></name></person-group><year>2008</year><article-title>Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade</article-title><source>Proc Natl Acad Sci U S A</source><volume>105</volume><fpage>8754</fpage><lpage>8759</lpage><pub-id pub-id-type="pmid">18559859</pub-id></element-citation></ref><ref id="r70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melchor</surname><given-names>JP</given-names></name><name><surname>Pawlak</surname><given-names>R</given-names></name><name><surname>Strickland</surname><given-names>S</given-names></name></person-group><year>2003</year><article-title>The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration</article-title><source>J Neurosci</source><volume>23</volume><fpage>8867</fpage><lpage>8871</lpage><pub-id pub-id-type="pmid">14523088</pub-id></element-citation></ref><ref id="r71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Qureshi</surname><given-names>IA</given-names></name><name><surname>Gokhan</surname><given-names>S</given-names></name><name><surname>Dinger</surname><given-names>ME</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name><name><surname>Mehler</surname><given-names>MF</given-names></name></person-group><year>2010</year><article-title>Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation</article-title><source>BMC Neurosci</source><volume>11</volume><fpage>14</fpage><pub-id pub-id-type="pmid">20137068</pub-id></element-citation></ref><ref id="r72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faghihi</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Modarresi</surname><given-names>F</given-names></name><name><surname>Van der Brug</surname><given-names>MP</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>St-Laurent</surname><given-names>G</given-names><suffix>3rd</suffix></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year>2010</year><article-title>Evidence for natural antisense transcript-mediated inhibition of microRNA function</article-title><source>Genome Biol</source><volume>11</volume><fpage>R56</fpage><pub-id pub-id-type="pmid">20507594</pub-id></element-citation></ref><ref id="r73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modarresi</surname><given-names>F</given-names></name><name><surname>Faghihi</surname><given-names>MA</given-names></name><name><surname>Patel</surname><given-names>NS</given-names></name><name><surname>Sahagan</surname><given-names>BG</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Lopez-Toledano</surname><given-names>MA</given-names></name></person-group><year>2011</year><article-title>Knockdown of BACE1-AS nonprotein-coding transcript modulates beta-amyloid-related hippocampal neurogenesis</article-title><source>Int J Alzheimers Dis</source><volume>2011</volume><fpage>929042</fpage><pub-id pub-id-type="pmid">21785702</pub-id></element-citation></ref><ref id="r74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Iyer</surname><given-names>MK</given-names></name><name><surname>Balbin</surname><given-names>OA</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Brenner</surname><given-names>JC</given-names></name><name><surname>Laxman</surname><given-names>B</given-names></name><name><surname>Asangani</surname><given-names>IA</given-names></name><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Kominsky</surname><given-names>HD</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Iyer</surname><given-names>HK</given-names></name><name><surname>Palanisamy</surname><given-names>N</given-names></name><name><surname>Maher</surname><given-names>CA</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year>2011</year><article-title>Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression</article-title><source>Nat Biotechnol</source><volume>29</volume><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">21804560</pub-id></element-citation></ref><ref id="r75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bero</surname><given-names>AW</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Roh</surname><given-names>JH</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Stewart</surname><given-names>FR</given-names></name><name><surname>Raichle</surname><given-names>ME</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year>2011</year><article-title>Neuronal activity regulates the regional vulnerability to amyloid-beta deposition</article-title><source>Nat Neurosci</source><volume>14</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">21532579</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="jad-48-3-jad150398-g001" orientation="portrait" position="float"><label>Fig.1</label><caption><p>RNAseq analysis. A) Schematic representation of the bioinformatics pipeline we used for RNAseq data analysis. This experimentally validated computational approach is suitable for the accurate measurement of gene expression and to discover and annotate novel RNA transcripts. B) Pie chart showing the number of annotated and non-annotated RNA transcripts expressed in at least one of the sequenced hippocampi RNA samples. C) qRT-PCR analysis of novel non-annotated lncRNAs identified by RNAseq. &#x003b2;-ACTIN was used as endogenous control to normalize gene expression analysis. On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene &#x003b2;-ACTIN. Error bars are S.D. Hippo: Hippocampus, PFC: Prefrontal Cortex, Cere: Cerebellum. D) Heatmap showing log2(FPKM) values and hierarchical clustering analysis for differentially expressed genes in LOAD versus control hippocampi.</p></caption><graphic xlink:href="jad-48-3-jad150398-g001"/></fig><fig id="jad-48-3-jad150398-g002" orientation="portrait" position="float"><label>Fig.2</label><caption><p>Differential expression analysis. A) Volcano plots revealing significant changes (Blue points; pfp&#x0200a;&#x0003c; &#x0200a;0.1: minimum reads coverage of 20)&#x000a0;in the expression of protein coding genes, antisense and lincRNAs in the hippocampi of AD patients (<italic>n</italic>&#x0200a;=&#x0200a;4) compared to control (<italic>n</italic>&#x0200a;=&#x0200a;4). B)&#x000a0;Technical validation of RNAseq differential expression analysis using qRT-PCR showing high degree of correlation between log2 fold change differences from RNAseq and qRT-PCR data for 6 different protein coding genes, 6 lincRNAs and 6 AS RNA transcripts.</p></caption><graphic xlink:href="jad-48-3-jad150398-g002"/></fig><fig id="jad-48-3-jad150398-g003" orientation="portrait" position="float"><label>Fig.3</label><caption><p>Dysregulation of protein-coding genes and pathways in LOAD. qRT-PCR expression analysis of <italic>TAC1</italic> (A) and <italic>SERPINE1</italic> (B) mRNA in postmortem brain tissues from four different regions of LOAD and age-matched control. Gene expression is normalized to CTRL. Cer&#x0200a;=&#x0200a;Cerebellum (24 patients, 20 controls), SFG&#x0200a;=&#x0200a;Superior frontal Gyrus (17 patients, 18 controls), Ectx&#x0200a;=&#x0200a;Entorhinal cortex (8 patients, 9 controls), Hipp&#x0200a;=&#x0200a;Hippocampus (12 patients, 10 controls). PGK1 was used as endogenous control to normalize gene expression analysis. Error bars are S.E.M.; <sup>&#x000a0;*</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.05; <sup>&#x000a0;**</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.01.</p></caption><graphic xlink:href="jad-48-3-jad150398-g003"/></fig><fig id="jad-48-3-jad150398-g004" orientation="portrait" position="float"><label>Fig.4</label><caption><p>Dysregulation of natural antisense
transcripts in LOAD. A) Schematic representation of the loci
expressing the newly discovered antisense RNAs HAO2-AS and EBF3-AS
(in black) and their overlapping protein coding genes (in blue).
B) qRT-PCR analysis of <italic>HAO2-AS</italic> and <italic>EBF3-AS</italic>
expression in commercially available RNA from different human
tissues. On the Y axe is depicted the expression of the analyzed
gene relative to the housekeeping gene &#x003b2;-ACTIN. C) qRT-PCR
analysis of <italic>HAO2-AS</italic> and <italic>EBF3-AS</italic> expression in RNA
extracted from hNSCs fractionated in different cellular
compartments: cytosol (Cyto), nucleoplasm (Nuc) and chromatin
(Chr). qRT-PCR expression analysis of <italic>HAO2-AS</italic> (D) and<italic>EBF3-AS</italic> (E) in postmortem brain tissues from four different
regions of LOAD and age-matched control. Cer&#x0200a;=&#x0200a;Cerebellum (24
patients, 20 controls), SFG&#x0200a;=&#x0200a;Superior frontal Gyrus (17
patients, 18 controls), Ectx&#x0200a;=&#x0200a;Entorhinal cortex (8 patients, 9
controls), Hipp&#x0200a;=&#x0200a;Hippocampus (12 patients, 10 controls). On the
Y axe is depicted the expression of the analyzed gene relative to
the housekeeping gene <italic>&#x003a0;&#x00393;</italic>K1. Gene expression is normalized
to CTRL. Error bars are S.E.M.; <sup>&#x000a0;*</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.05;<sup>&#x000a0;**</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.01.</p></caption><graphic xlink:href="jad-48-3-jad150398-g004"/></fig><fig id="jad-48-3-jad150398-g005" orientation="portrait" position="float"><label>Fig.5</label><caption><p>Dysregulation of long intergenic non-coding RNAs in LOAD. A) Schematic representation of the loci expressing the newly discovered lincRNAs AD-linc1 and AD-linc2 (in black). B) commercially available RNA from different human tissues. On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene &#x003b2;-ACTIN. C) qRT-PCR analysis of<italic>AD-linc1</italic> and <italic>AD-linc2</italic> expression in RNA extracted from hNSCs fractionated in different cellular compartments: cytosol (Cyto), nucleoplasm (Nuc) and chromatin (Chr). qRT-PCR expression analysis AD-linc1 (D) and AD-linc2 (E) in postmortem brain tissues from four different regions of LOAD and age-matched control. Cer&#x0200a;=&#x0200a;Cerebellum (24 patients, 20 controls), SFG&#x0200a;=&#x0200a;Superior frontal Gyrus (17 patients, 18 controls), Ectx&#x0200a;=&#x0200a;Entorhinal cortex (8 patients, 9 controls), Hipp&#x0200a;=&#x0200a;Hippocampus (12 patients, 10 controls). On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene <italic>&#x003a0;&#x00393;</italic>K1. Gene expression is normalized to CTRL. Error bars are S.E.M.; <sup>&#x000a0;*</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.05;<sup>&#x000a0;**</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.01.</p></caption><graphic xlink:href="jad-48-3-jad150398-g005"/></fig><fig id="jad-48-3-jad150398-g006" orientation="portrait" position="float"><label>Fig.6</label><caption><p>Altered lncRNAs are activity-dependent regulated and induced by A&#x003b2;. A) qRT-PCR showing the relative expression of glial (GFAP and S100&#x003b2;) and neuronal markers (DCX and NFH) and LOAD-dysregulated lncRNAs in commercially available RNA extracted from human neurons and human astrocytes. On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene &#x003b2;-ACTIN. Gene expression is normalized to astrocytes. B, C) Immunostaining of human NSCs after 21 days of differentiation <italic>in vitro</italic>. hNSCs can be differentiated into a mixed population of neural cells. Neurons are stained with &#x003b2;III-Tubulin (B) and MAP2 (C), while astrocytes are stained with GFAP (B). In both images cell nuclei are stained with DAPI. qRT-PCR analysis showing gene expression changes 1&#x0200a;h post KCl stimulation (D) and 48&#x0200a;h post A&#x003b2;<italic>&#x003c4;</italic><italic>&#x003c1;</italic><italic>&#x0025b;</italic><italic>&#x003b1;</italic><italic>&#x003c4;</italic><italic>&#x003bc;</italic><italic>&#x0025b;</italic><italic>&#x003bd;</italic><italic>&#x003c4;</italic> (E) of hNSCs differentiated for 21 days <italic>in vitro</italic>. On the Y axe is depicted the expression of the analyzed gene relative to the housekeeping gene &#x003b2;-ACTIN. Gene expression is normalized to non-treated and DMSO-treated cells respectively. Error bars are S.E.M.; <sup>&#x000a0;*</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.05; <sup>&#x000a0;**</sup><italic>p</italic>&#x0200a;&#x0003c; &#x0200a;0.01.</p></caption><graphic xlink:href="jad-48-3-jad150398-g006"/></fig><table-wrap id="jad-48-3-jad150398-t001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Samples Information. Clinicopathological information of the samples subjected to RNAseq analysis</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">CaseID</td><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1">Expired age</td><td rowspan="1" colspan="1">ApoE genotype</td><td rowspan="1" colspan="1">PMI</td><td rowspan="1" colspan="1">Case</td><td rowspan="1" colspan="1">Braak Stage</td><td rowspan="1" colspan="1">NIA-Reagan</td><td rowspan="1" colspan="1">RIN</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">95&#x02013;03</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">2/3</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">Ctrl</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">criteria not met</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">96&#x02013;16</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">Ctrl</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">criteria not met</td><td rowspan="1" colspan="1">6.5</td></tr><tr><td rowspan="1" colspan="1">96&#x02013;22</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">&#x0003e;90</td><td rowspan="1" colspan="1">3/3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Ctrl</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">criteria not met</td><td rowspan="1" colspan="1">8.6</td></tr><tr><td rowspan="1" colspan="1">96&#x02013;32</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">2/3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Ctrl</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">criteria not met</td><td rowspan="1" colspan="1">8.32</td></tr><tr><td rowspan="1" colspan="1">95&#x02013;18</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">3/3</td><td rowspan="1" colspan="1">2.33</td><td rowspan="1" colspan="1">AD</td><td rowspan="1" colspan="1">VI</td><td rowspan="1" colspan="1">high</td><td rowspan="1" colspan="1">6.9</td></tr><tr><td rowspan="1" colspan="1">96&#x02013;05</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">3/3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">AD</td><td rowspan="1" colspan="1">V</td><td rowspan="1" colspan="1">high</td><td rowspan="1" colspan="1">6.5</td></tr><tr><td rowspan="1" colspan="1">96&#x02013;11</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">3/3</td><td rowspan="1" colspan="1">2.83</td><td rowspan="1" colspan="1">AD</td><td rowspan="1" colspan="1">VI</td><td rowspan="1" colspan="1">high</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">96&#x02013;20</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">3/3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">AD</td><td rowspan="1" colspan="1">VI</td><td rowspan="1" colspan="1">high</td><td rowspan="1" colspan="1">6.7</td></tr></tbody></table></table-wrap><table-wrap id="jad-48-3-jad150398-t002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Filtering statistics. Number of spurious transcripts and total number of transcripts and genes after applying filtering strategy</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Transcript type</td><td rowspan="1" colspan="1">Before filtering</td><td rowspan="1" colspan="1">After filtering</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Intronic transcripts</td><td rowspan="1" colspan="1">643008</td><td rowspan="1" colspan="1">2803</td></tr><tr><td rowspan="1" colspan="1">Polimerase run-off</td><td rowspan="1" colspan="1">24426</td><td rowspan="1" colspan="1">108</td></tr><tr><td rowspan="1" colspan="1">Repeat transcripts</td><td rowspan="1" colspan="1">11533</td><td rowspan="1" colspan="1">82</td></tr><tr><td rowspan="1" colspan="1">Mapping errors</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">Total transcripts</td><td rowspan="1" colspan="1">1237780</td><td rowspan="1" colspan="1">154416</td></tr><tr><td rowspan="1" colspan="1">Total genes</td><td rowspan="1" colspan="1">800605</td><td rowspan="1" colspan="1">21697</td></tr></tbody></table></table-wrap><table-wrap id="jad-48-3-jad150398-t003" orientation="portrait" position="float"><label>Table 3</label><caption><p>Statistics of RNAseq data analysis. Number of sequencing reads before and after trimming, number of reads aligned to the human genome</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td rowspan="1" colspan="1">Sample</td><td rowspan="1" colspan="1">Original</td><td rowspan="1" colspan="1">Reads after</td><td rowspan="1" colspan="1">% Alignment</td></tr><tr><td rowspan="1" colspan="1">reads</td><td rowspan="1" colspan="1">after trimming</td><td rowspan="1" colspan="1">AD1</td><td rowspan="1" colspan="1">187514717</td><td rowspan="1" colspan="1">149308600</td><td rowspan="1" colspan="1">79.91</td></tr><tr><td rowspan="1" colspan="1">AD2</td><td rowspan="1" colspan="1">180318237</td><td rowspan="1" colspan="1">151072769</td><td rowspan="1" colspan="1">81.08</td></tr><tr><td rowspan="1" colspan="1">AD3</td><td rowspan="1" colspan="1">178521597</td><td rowspan="1" colspan="1">150407208</td><td rowspan="1" colspan="1">82.89</td></tr><tr><td rowspan="1" colspan="1">AD4</td><td rowspan="1" colspan="1">188604801</td><td rowspan="1" colspan="1">155834074</td><td rowspan="1" colspan="1">83.26</td></tr><tr><td rowspan="1" colspan="1">Ctrl1</td><td rowspan="1" colspan="1">177108169</td><td rowspan="1" colspan="1">143691181</td><td rowspan="1" colspan="1">75.05</td></tr><tr><td rowspan="1" colspan="1">Ctrl2</td><td rowspan="1" colspan="1">173894719</td><td rowspan="1" colspan="1">125465469</td><td rowspan="1" colspan="1">68.5</td></tr><tr><td rowspan="1" colspan="1">Ctrl3</td><td rowspan="1" colspan="1">164772379</td><td rowspan="1" colspan="1">134991306</td><td rowspan="1" colspan="1">79.42</td></tr><tr><td rowspan="1" colspan="1">Ctrl4</td><td rowspan="1" colspan="1">170053030</td><td rowspan="1" colspan="1">139609407</td><td rowspan="1" colspan="1">79.97</td></tr></tbody></table></table-wrap><table-wrap id="jad-48-3-jad150398-t004" orientation="portrait" position="float"><label>Table 4</label><caption><p>Pathway analysis. The integrated knowledge-based platform GeneGo was used to perform pathway analysis of differentially expressed protein coding genes in LOAD. The most enriched process networks are listed here</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Networks</td><td rowspan="1" colspan="1"><italic>p</italic> Value</td><td rowspan="1" colspan="1">Min FDR</td><td rowspan="1" colspan="1">Network Objects from Active Data</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Signal transduction_Neuropeptide signaling pathways</td><td rowspan="1" colspan="1">8.916E-04</td><td rowspan="1" colspan="1">5.573E-02</td><td rowspan="1" colspan="1">EDNRA (Galpha(q)-specific peptide GPCRs), GRP (GRP precursor), MCHR2, PRKAR1B (PKA-reg (cAMP-dependent)), PKD1L2, TAC1 (Substance P)</td></tr><tr><td rowspan="1" colspan="1">Neurophysiological process_Transmission of nerve impulse</td><td rowspan="1" colspan="1">1.230E-03</td><td rowspan="1" colspan="1">5.573E-02</td><td rowspan="1" colspan="1">SLC5A7 (CHT1), ADRB3 (Galpha(i)-specific amine GPCRs, Galpha(s)-specific amine GPCRs), HTR3B, SCN11A (NAV1.9), PRKAR1B (PKA-reg (cAMP-dependent)), TH (TY3H)</td></tr><tr><td rowspan="1" colspan="1">Muscle contraction</td><td rowspan="1" colspan="1">1.691E-03</td><td rowspan="1" colspan="1">5.573E-02</td><td rowspan="1" colspan="1">EDNRA (Galpha(q)-specific peptide GPCRs), ADRA1D (Galpha(q)-specific amine GPCRs), GUCA1C (GCAP), MYBPC1 (MYPS), CHRNA3 (nAChR alpha), TNNT2 (Troponin T, cardiac)</td></tr><tr><td rowspan="1" colspan="1">Development_Blood vessel morphogenesis</td><td rowspan="1" colspan="1">1.956E-03</td><td rowspan="1" colspan="1">5.573E-02</td><td rowspan="1" colspan="1">ADRB3 (Beta-3 adrenergic receptor, Galpha(i)-specific amine GPCRs, Galpha(s)-specific amine GPCRs), BMP4, EDNRA (EDNRA, EDNRB, Galpha(q)-specific peptide GPCRs), FGF10</td></tr></tbody></table></table-wrap><table-wrap id="jad-48-3-jad150398-t005" orientation="portrait" position="float"><label>Table 5</label><caption><p>HAO2-AS and EBF3-AS 5&#x02019; Rapid Amplification of cDNA Ends (RACE). PCR products from HAO2-AS and EBF3-AS 5&#x02019; RACE were cloned into pGEM-T Easy vector and Sanger sequenced. The sequencing product is highlighted in bold while AUAP and GSP3 primers sequences are underlined. Genomic coordinates are based on GRCh38 human genome assembly</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Transcript</td><td rowspan="1" colspan="1">5&#x02019; RACE Sequencing product</td><td rowspan="1" colspan="1">Genomic location of 5&#x02019; end determined by RACE</td><td rowspan="1" colspan="1">Genomic location of 5&#x02019; determined by RNAseq</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">HAO2-AS</td><td rowspan="1" colspan="1">GGCCACGCGTCGACTAGTACGGGGGGGGGGGGG</td><td rowspan="1" colspan="1">Chr1&#x0200a;:&#x0200a;119391704</td><td rowspan="1" colspan="1">Chr1&#x0200a;:&#x0200a;119391655</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CACTAAGTCTTTTTGGCAAGACAAGTACACTTGG</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CCATGGCCTGCATGTATGGATTGCATCCTGACTTG</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GGAAACTGGGTTGAACATTATTTCTCATGCACCAC</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">TTGACCAACTTGTCCCTGACTTCCTCATGG</td></tr><tr><td rowspan="1" colspan="1">EBF3-AS</td><td rowspan="1" colspan="1">GGCCACGCGTCGACTAGTACGGGGGGGGGGGGG</td><td rowspan="1" colspan="1">Chr10&#x0200a;:&#x0200a;129839551</td><td rowspan="1" colspan="1">Chr10&#x0200a;:&#x0200a;129839543</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">TTTTGAAAGAGATCACGTAGGAAAATCAGCTCCT</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">GTCCACAGACAGGACTGCAACCTGGTGTTGGTAC</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ACACCTGGCCCTGGGTCTAGACGCACACCTCTTT</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CCAAAAGACAGTGCAGCCCTGCTGGATGTGTGGC</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CCAGCAGATAAG</td></tr></tbody></table></table-wrap></floats-group></article>